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Abstract
The transition between soluble intrinsically disordered tau protein
and aggregated tau in neurofibrillary tangles in Alzheimer’s
disease is unknown. Here, we propose that soluble tau species can
undergo liquid–liquid phase separation (LLPS) under cellular condi-
tions and that phase-separated tau droplets can serve as an inter-
mediate toward tau aggregate formation. We demonstrate that
phosphorylated or mutant aggregation prone recombinant tau
undergoes LLPS, as does high molecular weight soluble phospho-
tau isolated from human Alzheimer brain. Droplet-like tau can also
be observed in neurons and other cells. We found that tau droplets
become gel-like in minutes, and over days start to spontaneously
form thioflavin-S-positive tau aggregates that are competent of
seeding cellular tau aggregation. Since analogous LLPS observa-
tions have been made for FUS, hnRNPA1, and TDP43, which aggre-
gate in the context of amyotrophic lateral sclerosis, we suggest
that LLPS represents a biophysical process with a role in multiple
different neurodegenerative diseases.
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Introduction
Tau protein is the major constituent of neurofibrillary tangles in
Alzheimer’s disease (AD) and of various other forms of intracellular
inclusions in frontotemporal dementias (FTDs). Tau is classically
described as a soluble neuron-specific microtubule binding (MTB)
protein; however, the connection between tau (mis)function and
neurodegeneration is uncertain. It is clear, for example, that post-
translational modifications (PTMs) and tau mutations predisposing
to aggregation are both associated with neurodegeneration.
Recently, soluble hyperphosphorylated high molecular weight tau
was identified as a bioactive form, which can be released and taken
up by neurons and initiate templated misfolding of cytoplasmic tau
in neurons (Takeda et al, 2015). This soluble hyperphosphorylated
tau is, however, clearly distinct from aggregated fibrillary tau in
neurofibrillary tangles, despite both being implicated in tau toxicity.
Tau is an exceptionally soluble protein, and the molecular mecha-
nisms that link soluble tau to aggregated tau are unknown. We now
report that tau—similar to several other neurodegenerative disease-
associated proteins such as the prion-domain harboring RNA bind-
ing proteins FUS, TDP43, hnRNPA1 (King et al, 2012)—can undergo
liquid–liquid phase separation (LLPS), and we suggest that this
observation may provide a biological mechanism for tau aggregation
in neurodegenerative diseases.
The longest isoform of tau in the human CNS contains a MTB
region that contains four pseudo-repeats (R1–R4) plus flanking
proline-rich regions (P1, P2, and P3; Gustke et al, 1994), a shorter
(40 aa) C-terminal tail, and a long (250 aa) flexible N-terminal
half of tau, which projects from the surface of microtubules in the
MT-bound state (Goode et al, 1997), and forms a polyelectrolyte
1 Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA
2 German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
3 Department for Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland
4 Department of Cell & Molecular Biology, St. Jude Children’s Research Hospital, Memphis, TN, USA
5 Max-Planck Institute for Molecular Cell Biology & Genetics, Dresden, Germany
6 Max-Planck Institute for Metabolism Research, Hamburg Outstation c/o DESY, Hamburg, Germany
7 CAESAR Research Center, Bonn, Germany
8 Howard Hughes Medical Institute, Chevy Chase, MD, USA
*Corresponding author. Tel: +1 617 230 7184; E-mail: swegmann@mgh.harvard.edu
**Corresponding author. Tel: +1 617 726 3987; E-mail: bhyman@mgh.harvard.edu
†These authors contributed equally to this work
ª 2018 The Authors. Published under the terms of the CC BY NC ND 4.0 license The EMBO Journal 37: e98049 | 2018 1 of 21
brush around fibrillary aggregates of tau (Sillen et al, 2005;
Wegmann et al, 2013). The lack of a fixed tertiary protein structure
classifies tau as an intrinsically disordered protein (IDP). Proteins
that contain intrinsically disordered regions often have multiple
biological functions (Wright & Dyson, 2014), and some of them
aggregate in protein aggregation diseases, such as huntingtin protein
in Huntington’s disease, a-synuclein in Parkinson’s disease, TDP43
and FUS in ALS, and tau in Alzheimer’s disease and tauopathies
(Uversky et al, 2008).
Recent studies revealed that the RNA binding and stress granule-
associated proteins FUS (Patel et al, 2015), hnRNPA1 (Molliex et al,
2015), and TDP43 (Conicella et al, 2016) have the ability to rever-
sibly form intracellular membrane-less organelles. These reversible
droplets represent physiologically active protein or protein-nucleic
acid “bioreactors” (Hyman et al, 2014), which form through a
process known as LLPS (Brangwynne et al, 2015). Such transient
membrane-less organelles have multiple cellular functions, such as
p-granule formation to establish intracellular gradients of RNA tran-
scription (Brangwynne et al, 2009), the enrichment of RNA binding
proteins in stress granules (Lin et al, 2015; Molliex et al, 2015),
concentrating transcription factors in nucleoli (Berry et al, 2015),
and the initiation of microtubule spindle formation (Jiang et al,
2015). However, the functional phase separation of nuclear proteins
was shown to be disrupted by C9orf72 GR/PR dipeptide repeats
(Lee et al, 2016) and is related to protein aggregation in neuro-
degeneration (Schmidt & Rohatgi, 2016).
In most cases, the phase transition of these proteins is driven by
so-called low complexity domains (LCDs) in their sequence, a term
of somewhat inconclusive nomenclature that is often used to
describe protein domains of low amino acid variance leading to
inhomogeneous charge distribution or polarity distribution along
the peptide backbone (Nott et al, 2015). For example, FUS, TDP-43,
and hnRNPA1 contain “prion-like” LCDs that drive their phase sepa-
ration. However, in the case of tau, no typical low complexity
domain (LCD) exists in the protein sequence, but the intrinsic disor-
der and the inhomogeneous charge distribution of full-length tau
(Lee et al, 1988) led us to postulate that tau may undergo a similar
phase separation. In fact, recent reports using recombinant tau
constructs support the argument that tau, despite having no defined
LCDs, can undergo LLPS facilitated by crowding agents or RNA
in vitro (Ambadipudi et al, 2017; Hernandez-Vega et al, 2017;
Zhang et al, 2017).
We now show that full-length human tau protein can efficiently
undergo LLPS to form condensed liquid tau droplets in cell physio-
logical conditions. We observed the formation of tau droplets not
only ex vivo for post-translationally modified recombinant tau, but
also in neurons in vitro and with strong evidence even in vivo, using
high molecular weight hyperphosphorylated tau isolated from
human Alzheimer brain. Importantly, tau LLPS is enabled and regu-
lated by physiological and pathological-like tau phosphorylation, by
disease-associated mutations, and can be induced in in vitro aggre-
gation conditions. Similar to FUS and hnRNPA1 proteins (Molliex
et al, 2015; Murakami et al, 2015; Patel et al, 2015), droplets of
pathological tau “mature” through a viscous gel phase into protein
aggregates; the tau aggregates become thioflavin-S positive, suggest-
ing the emergence of the beta-pleated sheet conformation present in
tau aggregates in vivo. It appears that the phase separation of tau at
physiological protein concentrations may be catalyzed by an
interplay of electrostatic interactions in the unstructured N-terminal
half of tau, combined with hydrophobic interactions of the C-term-
inal MTB domain, which can stabilize tau droplets possibly through
b-sheet structures. These findings complement and provide addi-
tional biological relevance to the recent reports showing in vitro tau
LLPS of repeat domain constructs at rather high concentrations
(Ambadipudi et al, 2017) and in the presence of aggregation trigger-
ing polyanionic RNA (Zhang et al, 2017).
Together, our data strongly support the hypothesis that intracel-
lular phase separation of tau leads to subcellular foci of high local
concentration of tau, which may be important for physiological
roles of tau, and—in the setting of aberrant phosphorylation or
disease-relevant pro-aggregation mutations—lead to tau aggrega-
tion. By analogy to hnRNPA1 (Molliex et al, 2015)-, TDP-43
(Conicella et al, 2016)-, FUS (Murakami et al, 2015)-, and C9orf72-
derived dipeptide repeats (Lee et al, 2016), tau LLPS could act to
initiate tau aggregation in AD and FTD. We suggest that protein
LLPS may be a biophysical mechanism underlying multiple protein
aggregation and neurodegenerative diseases.
Results
Intrinsically disordered tau protein can accumulate in droplet-
like assemblies in neurons
Several disordered proteins with LCDs have been shown to undergo
LLPS leading to liquid droplet formation in aqueous solution upon
increasing the molecular crowding in the solution (Mitrea et al,
2016). Cells use LLPS to reversibly assemble membrane-less orga-
nelles such as stress granules, p-granules, or nucleoli (reviewed in
Mitrea et al, 2016; Hyman et al, 2014). In a number of LLPS
proteins, including Ddx4 (Nott et al, 2014), domains of low amino
acid complexity introduce an unequal charge distribution along the
protein backbone resulting in multivalency of these polypeptides
with alternating patches of high positive or negative charge densi-
ties (Toretsky & Wright, 2014). The phase separation of these
proteins is often driven by electrostatic interactions within the
LCDs, or between them. Tau is intrinsically disordered (Fig 1A,
Appendix Fig S1), and the distribution of charges in the longest
human isoform of tau (2N4R, 441 aa) at physiological pH 7.4 shows
per se a similar multivalent pattern (Wegmann et al, 2013): The
N-terminus (aa 1–120) has a negative net charge, the middle
domain (aa 121–250) has a large excess of positive charges, the
repeat domain (TauRD, aa 251–390) has a moderate excess of
positive charges, and the C-terminus (aa 391–441) is negatively
charged (Fig 1B).
Based on this knowledge about the disorder and inhomoge-
neous charge distribution of tau, we postulated that human tau
may also be able to undergo LLPS in neurons. To test this
hypothesis, we expressed GFP-tagged full-length tau (GFP-tau441)
in primary cortical mouse neurons. The expression of GFP-tau441
led to the formation of mobile intracellular droplet-like tau
accumulations in the cytosol (Fig 1C, Movies EV1–EV3), and
fluorescence recovery after photobleaching (FRAP) of intraneu-
ronal GFP-tau441 droplets revealed a fast recovery rate with an
immobile tau molecule fraction of 30% (Figs 1D and EV1A).
Some droplet-like tau accumulations in axons of neurons grown
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in microfluidic chambers moved retro- as well as anterograde
(Fig 1E, Movie EV4). Interestingly, GFP-tau441 droplets (Movies
EV1–EV3) appeared less mobile compared to droplets formed by
the N-terminal projection domain of tau441 (aa 1–256), GFP-
tau256 (Movies EV5–EV7), maybe because of the ability of
full-length GFP-tau441 but not GFP-tau256 to bind microtubules
via the repeat domain.
We did not observe the fusion or fission of GFP-tau441 droplets
in neurons, which can be seen as a typical behavior of liquid
droplets. However, the observed FRAP recovery of the GFP-tau
droplets excludes the possibility that the observed spherical droplets
resemble large tau aggregates previously reported for mutant tau
expressed in neurons (Hoover et al, 2010). Tau aggregates induced
in HEK TauRDP301S-CFP/YFP cells, or GFP-polyQ aggregates in
A
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primary neurons, did not show recovery after photobleaching
(Fig EV1B and C), whereas soluble GFP-tau in the cytosol and
bound on microtubules showed fast recovery (Fig EV1D). More-
over, the expression of wild-type tau does not lead to intracellular
tau aggregation, neither in vitro (Lim et al, 2014) nor in vivo.
Furthermore, GFP-tau441 droplets did not co-localize with
membrane-bound organelles like lysosomes (Fig 1F), endosomes
(Appendix Fig S2A), or the endoplasmic reticulum (ER,
Appendix Fig S2B).
Interestingly, when tau441 N-terminally fused to the fluorescent
protein Dendra2, Dendra2-tau441, was expressed in the cortex of
living wild-type mice upon stereotactical injection of AAV Dendra2-
tau441 into the somatosensory cortex, two-photon imaging through
a cranial window revealed a heterogeneous distribution of uncon-
verted green Dendra2-tau441 with spherical droplet-shaped accumu-
lations in the cell bodies of neurons in cortex layer 2/3 (Fig EV1E,
neuron #1–3). Some of these accumulations also occurred along
neuritic projections (Fig EV1E, #4–6). In contrast, the distribution of
GFP in neurons of the control AAV GFP-injected hemisphere was
homogeneous in cell bodies and projections of transduced neurons.
These data indicated that tau LLPS may also occur in the living
brain.
Notably, in N2a cells, GFP-tau droplets could mostly be
observed in cells with sufficiently high GFP-tau expression levels
(Fig 1G), whereas in primary neurons, droplets could also occur in
neurons with rather low or medium GFP-tau441 expression levels.
This indicated that tau LLPS in neurons may be regulated by addi-
tional factors. In neurons, tau is phosphorylated at multiple sites
(Fig EV1F; Iqbal et al, 2005). Many of tau’s physiological and
pathological phosphorylation sites are located in the positively
charged middle domain of the N-terminal half and in the repeat
domain (Johnson & Stoothoff, 2004), where phosphorylation
causes a local increase or a change in domain charge from positive
to neutral or negative, and hence can change intra- and inter-
molecular interactions of tau. However, most previous in vitro
studies on tau aggregation utilized recombinant non-phosphory-
lated tau from Escherichia coli, and in these studies, tau LLPS has
not been observed.
◀ Figure 1. Droplet-like condensation of intrinsically disordered human tau protein in neurons.A Protein sequence and disorder prediction (PONDR) of the longest human tau isoform [2N4R, 441 amino acids (aa)]. The highly disordered N-terminal half (projection
domain) contains two N-terminal repeats (N1, N2) and two proline-rich regions (P1, P2). The repeat domain (TauRD) consists of four pseudo-repeats (R1–R4),
can transiently adopt short stretches of b-strand structure in R2 and R3, facilitates microtubule binding together with P2 + P3, and mediates the aggregation of tau.
B Single amino acid and average (sliding window of 6 aa) charge distribution along the tau441 sequence (at pH 7.4) reveal the following charged domains in tau441:
the negatively charged N-terminal end (aa 1–120), a strongly positively charged middle domain (aa 121–250), the positively charged TauRD (aa 251–400), and a
negatively charged C-terminal end (aa 401–441).
C Intracellular droplet-like accumulations of GFP-tau441 (white arrows) in primary cortical mouse neurons. Expression of GFP alone does not lead to droplets. Droplet
dynamics in neurons is shown in Movie EV1.
D FRAP reveals incomplete recovery of droplet-like tau in neuronal cell bodies indicating an immobile fraction of GFP-tau441 molecules of 30%.
E Neurons growing in microfluidic chambers extend their axons in microgrooves (Takeda et al, 2015). Time-lapse imaging (#1–5, time interval 3 s) shows the
movement of droplet-like GFP-tau441 (white arrows) in axons over time.
F Immunofluorescent labeling of neurons expressing GFP-tau441 shows that tau accumulations (white arrows) do not co-localize with lysosomes (LAMP1).
G In murine neuroblastoma cells (N2a) expressing GFP-tau441, droplet-like tau occurs in cells having a critical GFP-tau441 concentration (white star). In cells with low
expression level (white square), GFP-tau binds to microtubule bundles; in cells with medium GFP-tau441 (white circle), excess GFP-tau441 fills the cell bodies. The
graph shows the GFP fluorescence intensity in cell bodies with (pink) and without (gray) droplets. Cross-sectional profiles of cells with droplets suggest a similar tau
concentration of GFP-tau on microtubules (white lines, black traces) and in droplets (pink lines and traces).
Data information: In (D), data are presented as mean  s.e.m., n = 9 droplets; data have been fitted with a one-phase exponential fit, r2 = 0.08215. In (G), average
fluorescence intensity in cell bodies is plotted as mean  s.e.m., n = 45 for “ droplets”, n = 17 for “+ droplets”.
▸Figure 2. Liquid droplet characteristics of p-tau441.A Qualitative distribution of phosphorylation sites in p-tau441 [pS68/69, pT153, pT175, pT181, pS184, pS199, pS202, pT205, pS210, pT212, pS214, pT217, pT231, pS235,
pS262, pS324, pY310, pS316, pS396, pS404, pS422 (Mair et al, 2016)]. The charge at pH 7.4 of domains in unphosphorylated tau441 is indicated as well.
B Liquid–liquid phase separation (LLPS) of p-tau441 in presence of molecular crowding (12.5% w/v Ficoll-400). No phase separation is observed without crowding
agent or in the absence of p-tau441 protein.
C Liquid droplets formed by p-tau441 in the presence of 10% (w/v) PEG were negative stained with uranyl-acetate and visualized by transmission electron microscopy
(TEM). p-tau441 droplets are decorated with gold particles after immunogold labeling using anti-tau antibody K9JA.
D Shortly after formation (15 min), p-tau441 droplets stop to coalesce and often occur as doublets or triplets. With time (60 min), droplets grow in size but remain
colloidal. Droplet fusion is shown in Movie EV1.
E p-tau441 droplets (in buffer with 10% PEG) exhibit glass surface wetting properties characteristics for liquids.
F Phase diagram of tau LLPS (p-tau441 concentration (lM) versus PEG concentration (% w/v).
G In conditions modeling the intraneuronal environment ( 2 lM tau, 10% PEG, pH 7.5), p-tau441 droplets can form at very high NaCl concentrations (up to 3 M
NaCl) in the buffer. Guanidinium hydrochloride (GdmHCl) prevents p-tau441 LLPS at 3 M; at this concentration, tau aggregates become visible. The chaotropic salt
sodium thiocyanate (NaSCN) can inhibit LLPS with increasing concentration, whereas droplets become larger in the presence of the cosmotropic salt ammonium
sulfate ((NH4)2SO4). Urea, which denatures proteins by unfolding secondary structures, prevents p-tau441 LLPS. n = 3 per condition, determined after 3 h.
H Brightfield images for p-tau441 LLPS under different salt conditions graphed in (G).
I The addition of 10% 1,6-hexanediol to p-tau441 droplets substantially reduced the amount of tau droplets formed.
Data information: In (F) and (G), the phase diagrams show the average of three measurements.
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Phosphorylated human full-length tau undergoes LLPS in vitro
We decided to describe the conditions for tau LLPS in more detail
and produced recombinant full-length human tau (p-tau441, aa
1–441; Fig 2A) in SF9 insect cells, which are able to introduce
PTMs including phosphorylation into recombinant tau (Tepper
et al, 2014). Previously, the phosphorylation sites found in
p-tau441 by mass spectrometry were reported to be similar to the
phosphorylation of tau extracted from AD brains (Mair et al,
2016; Fig EV1G), with phosphorylation in the repeat domain (R1–
R4), in the proline-rich region (P1 + P2), and some in the N-term-
inal insets (N1 and N2) of tau441 (Fig 2A). Here, we used Sf9
p-tau441 protein from the same source that was expressed and
purified under identical conditions, and verified most of the
A
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reported phosphorylation sites in p-tau441 by Western blot analy-
sis (Fig EV1G).
As hypothesized for LLPS proteins, we were able to observe the
rapid formation of liquid p-tau441 droplets in solution upon the
addition of crowding agents Ficoll (12.5% w/v; Fig 2B) or polyethy-
lene glycol (PEG, 10% w/v; Fig EV2A) to mimic the intracellular
crowding of 150 mg/ml proteins present in the cytosol. No
droplets were observed for solutions of p-tau (2–10 lM) without
crowding agent and for crowding agent without tau protein
(Fig 2B), or for crowding agent with control protein GFP at the same
concentration (Fig EV2A). We verified that the observed phase-
separated droplets contain tau protein by adding PEG to fluores-
cently labeled p-tau441-Alexa568, and show the integration of
fluorescently labeled tau protein into the droplets (Fig EV2B).
Analyzing the fluorescence intensity of ptau441-a568 droplets using
confocal images, we measured an apparent p-tau441 concentration
of 34.3  6.4 lM p-tau441 in the droplets and 3.6  0.3 lM
remaining in the solution (mean  s.d.; 5 lM p-tau441-a568 start-
ing concentration and 10% PEG; Fig EV2B and C). This value does
not consider fluorophore–fluorophore quenching and other effects
caused by the highly crowded and viscous environment in the
droplets and thus likely underestimates the actual droplet p-tau441
concentration. When using the crowding agent dextran to initiate p-
tau441 LLPS, fluorescently labeled dextrans of different molecular
weights (mean MW = 3, 20, and 70 kDa) remained excluded from
the droplets, as indicated by confocal imaging (Fig EV2D). In
contrast, monomolecular dyes with affinity to hydrophobic protein
regions, such as thioflavin-S, methylene blue, and viscous aqua,
immediately co-partitioned into the droplets (Fig EV2E); however,
the dye fluorescence in the droplets may be further enhanced by the
inhibition of free molecular rotation of the dye due to a higher
viscosity in the droplets.
Interestingly, at very high p-tau441 concentration (50 lM), spon-
taneous LLPS occurred at the outer edge of cover slip deposited
solution droplets, where the protein concentration is highest due to
evaporation and surface tension effects, even in the absence of
crowding agents (Fig EV3A, Movie EV8). This indicates that tau
phase separation depends on a critical local protein concentration.
However, the concentration of p-tau441 in these droplets has to be
higher than the starting concentration of 50 lM, suggesting that the
apparent droplet concentration we measured using fluorescently
labeled p-tau441 in the presence of PEG (34 lM) may underesti-
mate the actual concentration by 30%. In solutions with the poly-
meric crowding agents Ficoll, PEG, and dextran, excluded volume
effects can induce the critical concentration and trigger tau LLPS at
lower tau solution concentrations. Indeed, we found that solutions
of 10% (w/v) ethylene glycol and glucose, which are the mono-
meric analogs of PEG and dextran, failed to induce tau LLPS at the
same concentrations (10% w/v crowding agent, 10 lM p-tau441;
Fig EV3B).
Tau forms stable droplets with initial liquid phase behavior
Tau droplets, when directly adsorbed onto electron microscopy
grids right after preparation (Fig 2C), differed in size with diameters
of 0.1–1.0 lm and reached diameters up to 10 lm when left in
solution (Fig 2B). The tau droplets were mobile while in solution
and, immediately after LLPS, able to coalesce (Movie EV9). After
15 min, however, the fusion of droplets was largely prevented
(Fig 2D), and after longer incubation times (> 1 h), the droplets
sunk down (likely driven by gravity due to higher protein density
than the surrounding liquid phase) and coated the bottom glass
surface (Fig 2E).
Next, we tested whether tau LLPS could occur at physiologically
relevant tau concentrations, intracellular molecular crowding (50–
400 mg/ml macromolecular density; Fulton, 1982), and electrolyte
concentrations (100–200 mM; Lodish et al, 2000) conditions. The
microscopic (i.e., visible in conventional light microscopy with a
63× objective) formation of p-tau441 droplets could be observed at
PEG concentrations ≥ 5% (crowding of ≥ 50 mg/ml macro-
molecule density without tau protein) and at a critical protein
concentration of 1.0 lM (Fig 2G). Notably, the amount of tau
needed for in vitro LLPS induced with the neutral molecule PEG
likely differs from the tau concentration critical for LLPS in a
neuron, because (i) the intraneuronal distribution of tau is highly
heterogeneous (usually high in the axon and low in the soma and
dendrites), (ii) different isoforms and post-translational modified
and truncated forms of tau coexist, (iii) the pool of free soluble tau
released from microtubules is highly dynamic depending on phos-
phorylation, and (iv) multiple other binding partners of tau have
been identified that could deplete tau from the free soluble pool
available for LLPS. Recently, it has also been shown that the usual
distribution of tau in neurons can be changed upon exposure to
A-beta, which can induce the local transcription of tau in dendrites
as well (Zempel & Mandelkow, 2015; Li & Go¨tz, 2017).
However, early studies performed on neuronal cells (Drubin
et al, 1985) suggested an intracellular tau concentrations of 1–3 lM.
Furthermore, a tubulin concentrations of 3% total protein
(20 lM tubulin; Hiller & Weber, 1978), average [tubulin: tau]
ratios of [17:1] (Drubin et al, 1985), and 30–50% of unbound free
tau (Ackmann et al, 2000) have been reported; from these numbers,
a tau protein concentration of 0.5–2 lM appears to be a reason-
able estimate. In addition, we performed new experiments on
human cortical tissue to estimate the intraneuronal tau concentra-
tion in human cortex. Using a combination of stereological counting
of neurons in human cortical volume and tau concentration
measurements in brain lysates by ELISA, we estimated the intra-
neuronal tau concentrations between 1.68  0.68 lM and
6.84  0.42 lM in the human brain (for calculations see
Appendix Supplementary Methods and Appendix Tables S1–S3).
This calculation intentionally underestimates the actual local
concentration of tau because it does not take into account the rela-
tive concentration of tau in subcellular regions like the axon hillock
and does not account for the volume of the neurons occupied by
vesicular structures that lack tau, such as the rather large nucleus,
mitochondria, and the ER and Golgi. Nonetheless, a p-tau441
concentration of 1.0 lM that we found to be critical for micro-
scopic LLPS at 10% PEG in vitro can thus be seen as relevant for
intraneuronal tau LLPS in the human brain.
For many LLPS proteins such as the helicases Ddx4 and LAF-1
and hnRNPA1, arginine-rich positively charged sequences (e.g., RGG
boxes, RRMs, SR repeats) drive their LLPS in a ionic strength depen-
dent manner (reviewed in Mitrea et al, 2016). Interestingly, p-tau441
droplet formation appeared to be insensitive to increasing salt condi-
tions (≤ 1 M NaCl), suggesting that shielding of electrostatic interac-
tions had a small effect on LLPS of p-tau441. Neither very high (pH
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9.5) or low (pH 3.0) pH of the buffer, nor high concentrations
(≤ 1 M) of other mono- (KCl) or bivalent (MgCl2) cation salts did
effect tau droplet formation (Fig EV3C and D). Indeed, we were able
to observe droplet formation up to 3 M NaCl, whereby droplets
deformed and adhered fast to the supporting glass surface at
NaCl > 1 M (Fig 2G and H). Interestingly, p-tau441 droplet forma-
tion could be reduced and even prevented when applying chaotropic
salts such as guanidinium hydrochloride (GdmHCl) and sodium
thiocyanate (NaSCN) at concentrations ≥ 0.5 M (Fig 2H). Notably,
1 M GdmHCl induced tau aggregates on the glass surface, whereas
1 M NaSCN prevented visible tau droplets or aggregates. Interest-
ingly, when adding the cosmotropic salt ammonium sulfate
((NH4)2SO4), tau droplets became substantially larger in diameter
(Fig 2H). According to the Hofmeister series of salts (Hofmeister,
1888), chaotrope salts like NaSCN can weaken the stability of
proteins and protein assemblies that are stabilized by hydrophobic
interactions, whereas “neutral” salts, such as NaCl and KCl, or
kosmotropic salts like (NH4)2SO4 can promote hydrophobic interac-
tions in and between proteins (Sawyer & Puckridge, 1973). Further-
more, 1,6-hexanediol (10% w/v), an aliphatic alcohol that weakens
hydrophobic interaction and can inhibit the LLPS of p-granules and
stress granules (Patel et al, 2007; Kroschwald et al, 2015), also
partially suppressed p-tau441 droplet formation (Fig 2I). The chao-
tropic salt and hexanediol sensitivity of p-tau441 phase separation
could, for example, be attributed to hydrophobic interactions
between short b-strands that can form in the repeat domain of the C-
terminal half of tau (hexapeptide motifs PHF6* and PHF6 in the
beginning of repeat 2 and 3; Von Bergen et al, 2005). Indeed, the
addition of urea, which denatures proteins by destabilizing their
secondary structure and protein folding, efficiently eliminated all
droplet formation (Fig EV3E). Furthermore, we found that the C-
terminal half of p-tau441 alone, p-tauCt (aa 242–441), was able to
undergo phase separation in a NaCl-insensitive (≤ 1 M NaCl)
manner as well (Fig EV4). Similar observations were very recently
reported for the phase separation of the tau repeat domain only
(Ambadipudi et al, 2017). To evaluate whether interactions of the
repeat domain were essential for LLPS of tau, we also expressed the
N-terminal (aa 1–256) half of tau441 in Sf9 cells, p-tau256, and
tested its LLPS characteristics (Fig EV5, Movie EV10). In comparison
with p-tau441 and p-tauCt, droplet formation of p-tau256 needed
slightly higher protein (5 lM) and PEG (10%) concentrations
and was inhibited in buffer containing ≥ 500 mM NaCl (Fig EV4F)
but not by hexanediol (Fig EV4G), thus likely driven by electrostatic
interactions. These data suggest that the N-terminal half of tau
contributes to the phase separation of full-length tau through electro-
static interactions. It seems unlikely but cannot be ruled out that
concentrations of N-terminally truncated tau, sufficiently high for
LLPS, exist in neurons, because tau is substrate for different proteases
(Arai et al, 2005; Wang et al, 2010), and N-terminal fragments are
commonly found in the healthy and AD brain (Fig EV4H). The disor-
dered N-terminal projection domain [(Mukrasch et al, 2009); Fig 1A]
harbors short serine- and proline-rich domains of low amino acid
complexity (Appendix Fig S1B), which may contribute to tau LLPS
behavior. Interestingly, the function of the large flexible unstructured
N-terminal half (amino acids 1–250) of tau is still uncertain, but it
has been shown that conformational changes of the N-terminal half
are involved in pathological “misfolded” forms of tau (Wolozin &
Davies, 1987; Carmel et al, 1996; Jeganathan et al, 2006).
Together, these data show that tau LLPS is a phenomenon that
can occur at relevant tau protein concentrations and crowding
conditions. Tau LLPS seems to be driven by a complex combination
of electrostatic and hydrophobic interactions.
Phosphorylation drives tau LLPS
Electrostatic forces are often predominant drivers for the LLPS of
IDPs or protein domains (Mitrea et al, 2016). Phosphorylation intro-
duces negative charges into proteins and changes the charge distri-
bution and the electrostatic interactions along the polypeptide
backbone, and hence also the LLPS characteristics of proteins. For
example, phosphorylation regulates LLPS of nephrine (Li et al,
2012), FUS (Monahan et al, 2017), and RNA binding protein CPEB4
(Guille´n-Boixet et al, 2016). Phosphorylation is also the major type
of PTMs in tau (Morris et al, 2015), and more than 80 potential
phosphorylation sites can be found in the amino acid sequence of
tau (Reynolds et al, 2008).
Under normal conditions, phosphorylation at distinct sites initi-
ates the dissociation of tau from MTs, and normal intraneuronal
tau appears to be phosphorylated at different sites (Fig EV1F). To
evaluate the role of phosphorylation for tau LLPS, we compared
the ability of tau proteins with different degrees of phosphorylation
to undergo phase separation. We tested two different p-tau441
constructs for LLPS (Fig 3A and B): (i) p-tau441 produced in SF9
insect cells (Tepper et al, 2014; Mair et al, 2016), which carries an
average of 12 phosphate groups, and for which we confirmed
the presence of most reported phospho-sites by Western blot
(Fig EV1G), (ii) alkaline phosphatase digested p-tau441, deP-
tau441, with an average of 4–5 phosphates. (Suggested remain-
ing sites: pT153, pT181, pS214, pS217, pT231; Mair et al, 2016.)
deP-tau441 dephosphorylation is indicated by a down-shift on the
Western blot and the lack of immunoreactivity for PHF1 and 12e8
antibodies (Fig 3B). Both phosphorylation states (p-tau441 and
deP-tau441) led to rapid droplet formation after the addition of
PEG (Fig 4C; protein concentration = 2 lM, 50 mM NaCl).
However, the droplet formation rate and final droplet size were
lower for deP-tau441 compared to p-tau441 (Fig 3D). p-tau441
droplets reached a maximum volume of 80 lm3 after 90 min; at
longer incubation times (> 90 min), the p-tau441 droplet size
decreased slightly, and the droplets started to show aggregate-like
structured regions at the droplet surface and deformed from the
previous spherical shape (Fig 3D, individual droplet gallery).
Droplet fusion (= coalescence) did not occur at time points
> 15 min. For deP-tau441, a similar trend was observed, with a
maximum droplet volume of 50 lm3 at 120 min after the addi-
tion of PEG. The observed drop in average p-tau441 and deP-
tau441 droplet volume coincided with the time point of adsorption
of tau droplets on the supporting glass surface, which may have
caused the depletion of the larger droplets from the solution.
Notably, the droplet growth depends on multiple parameters such
as fusion, fission, Ostwald ripening, and gelation of the droplets.
The size measurements can thus mostly be used for a qualitative
statement of increased droplet formation propensity with increas-
ing phosphorylation.
Non-phosphorylated recombinant tau441 (produced in E. coli)
was unable to form droplets in presence of crowding agent, even
after extended incubations times of 12 h. We speculated that the
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negative charges introduced by phosphorylation were a driving
factor of tau LLPS. To test this hypothesis, we produced the phos-
pho-mimetic mutant, tau441 E17 [=17 threonine and serine resi-
dues along the sequence of tau441 mutated into glutamate to
introduce negative charges (Li et al, 2011)], in E. coli and
monitored the droplet formation. Compared to p-tau441 and
deP-tau441, tau441E17 showed delayed droplet formation at
strongly reduced rates and reached small final droplet volumes
(3 lm3) and volume fractions. Moreover, by introducing minor
levels of phosphorylation at specific sites in E. coli-derived recom-
binant tau441 by in vitro phosphorylation with kinase MARK2
(tau441 + MARK2) (Fig 3A and B), droplet formation could be
rescued but at a much lower rate and with substantially smaller
final droplet volumes of only 6 lm3 (Fig 3D). In vitro tau
A
C
D
B
Figure 3. Phosphorylation regulates tau LLPS.
A Scheme indicating the location of most abundant phosphorylations in the tau constructs examined: phosphorylated tau441 expressed in SF9 cells (p-tau441),
dephosphorylated tau (deP-tau441) produced by alkaline phosphatase digestion of p-tau441. tau441 (produced in Escherichia coli) in vitro phosphorylated with
MARK2 at indicated sites (two major and two minor sites), and phospho-mimic tau441E17 (17 glutamates at serine/threonine sites: S46, T50, T69, T111, T153, T175,
T181, S199, S202, T205, T212, T217, T217, T231, T235, S396, S404, S422) produced in E. coli.
B Western blot analysis of the different phospho-tau constructs displayed in (A). Equal amounts of tau proteins were probed for phospho-epitopes pS396/pS404
(antibody PHF1) to test the phosphorylation of p-tau441 and deP-tau441 and for pS262/pS356 (antibody 12e8) to verify tau441 + MARK2 phosphorylation. tau441
and tau441E17 are not phosphorylated.
C All phosphorylated tau constructs and the pseudo-phosphorylated tau441E17 show droplet formation (white arrows) in the presence of molecular crowding (after
3 h), whereas non-phosphorylated tau441 from E. coli does not.
D Droplet growth rate and size (= spherical volume) vary between phospho-tau constructs: p-tau441 droplets grow fastest and occupy the largest volume fraction.
After reaching a maximum mean droplet size, both p-tau441 and deP-tau441 both start to deform and develop “substructures” on the droplet surface. Gallery of
p-tau441 and deP-tau441 droplets at indicated (red and white star) time points.
Data information: In (D), data of spherical volume and volume fraction are displayed as mean droplet volume  s.d., with n = 25–120 droplets per condition and time
point.
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phosphorylation by MARK2 specifically targets two major sites
(S262 and S356) and two minor sites (S293 and S324) in the
repeat domain and causes the physiological detachment of tau
from microtubules (Timm et al, 2003; Schwalbe et al, 2013). For
both tau441E17 and tau441 + MARK2, we observed droplet coagu-
lation but not the formation of structured regions inside the
droplets or on the droplet surface.
These data indicate that pathophysiological phosphorylation of
tau (as in p-tau441, Fig EV1G) as well as physiological non-patholo-
gical tau phosphorylation that detaches tau from microtubules, for
example, by MARK2, creates an electrostatic environment that can
efficiently enhance the kinetics of tau LLPS. The growth rate and
extent of droplet formation depended on the degree of phosphoryla-
tion, whereby the introduced negative charges (as in tau441E17)
could only account for some of this effect; it seems likely that the
addition of phosphate groups at certain positions is relevant for the
conformational changes that can lead to LLPS of tau. The lack of tau
droplet coalescence suggests a fast increase in the viscoelasticity of
phospho-tau droplets preventing droplet fusion (Abbott, 1977; Gu
et al, 2011); this is characteristic for the “maturation” of liquids into
A
D
F G
E
B C
Figure 4. p-tau droplets mature and initiate tau aggregates.
A FRAP of whole droplets shows the exchange of tau molecules between droplets and the surrounding solution. When recorded at different time points after droplet
initiation (0, 15, 30, 45, 60 min), whole droplet FRAP unravels that p-tau441-dl488 exchange between the droplets and the solution is efficient immediately after
droplet initiation and decreases to  40% after only 15 min.
B FRAP of a small fraction of the droplets is used to assess the mobility of tau molecules in the droplets. The immobile molecule fraction in the droplets increases
slowly during  45 min at maintained recovery rates. After 60 min, almost no p-tau441-dl488 mobility in the droplets (= no recovery) could be observed (15 lM
protein; 10% dl488-labeled protein; 10% PEG).
C One-day-old p-tau441 droplets can be separated from the medium by centrifugation; they maintain droplet shape when resuspended in absence of crowding agent,
indicating a gel-like polymerized texture.
D Extended incubation of p-tau441 droplets leads to formation of fibrillary tau protein aggregates in and around the droplets after 1 day; aggregates increase over
time (10 days) and are visible as amorphous aggregated structures in electron microscopy.
E Thioflavin-S, which increases its fluorescence 10-fold upon binding to b-pleated sheets in amyloid-like protein aggregates, readily co-partitions into p-tau441
droplets. After 4 h, the diffuse increase in fluorescence in some droplets may be due to the viscous droplet environment. After 24 h, ThioS fluorescence appears
concentrated in tau aggregates on the droplet surface, indicating amyloid fibril cross-b structure content of these aggregates.
F Atomic force microscopy topography of 1-day-old p-tau441 droplets adsorbed to the glass surface reveals a rather high resistance of tau droplets against scanning
forces of > 250 pN and the protrusion (stars in contour plots) of stable tau aggregates from the droplet surface. Height profiles (left) taken along sections indicated in
the topography (right). Color scale bar on top indicates vertical height profile.
G Aged (3 days, 10 lM p-tau441 with 10% PEG at room temperature) p-tau droplets initiate tau aggregation in HEK cells expressing TauRDP301S-CFP/YFP after 10 h
(0.5 lM tau with or without 0.8% lipofectamine and 0.5% PEG) (white arrows). No tau aggregation was observed in cells treated with only PEG or soluble p-tau441.
Data information: In (A, B), dots represent raw data, and lines are single exponential fits, n = 3–4 droplets/condition.
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hydrogels (Kato et al, 2012). The subsequent deformation of
p-tau441 droplets and the formation of tau aggregates in the droplets
are strong indicators for the further transition of the tau droplets
from a gel-like into an aggregate state of lower energy; a similar
maturation has been described for FUS (Patel et al, 2015). The
aggregation of tau can be detected as droplet deformation and the
growth of non-spherical solid aggregates.
Tau LLPS precedes aggregation in vitro
Liquid droplets assembled from TDP-43 (Conicella et al, 2016) and
FUS (Burke et al, 2015; Patel et al, 2015) can transition from a
reversible liquid state into a gel-like state of higher viscosity and
further into amyloid-like or amorphous protein aggregates. A simi-
lar transition can lead to aberrant stress granule dynamics of
C9orf72-derived dipeptide repeats, which plays a role in the
pathogenesis in amyotrophic sclerosis (ALS; Taylor et al, 2016). In
different neurodegenerative diseases such as AD and FTD, hyper-
phosphorylated tau is found in pathological tau aggregates (Gong
et al, 2005), and the phosphorylation pattern of p-tau441 has been
shown to be similar to that found in tau aggregates from AD
brains (Mair et al, 2016). We next tested whether the hardening
and deformation that we observed for droplets formed from phos-
phorylated tau describes a similar “maturation” from a liquid
phase to a gel-like and finally an irreversibly aggregated state,
similar to FUS and TDP-43.
To evaluate the transition from a liquid to a gel-like state, which
is characterized by an increase in viscoelasticity and, hence, a
decrease in molecular diffusion rates in the gel state (Kato et al,
2012), we performed FRAP microscopy of freshly prepared p-tau441
droplets that contained 10% of fluorescently labeled protein of the
same kind (p-tau441-dl488). When bleaching the entire droplets
(Fig 4A) at different times after droplet initiation (addition of 10%
PEG), we found a rapid decrease of recovery in the first 15 min and
virtually no recovery after 30 min. This suggested that the exchange
of tau molecules between the droplets and the surrounding solution
was inhibited, and indicated that the liquid droplets matured rapidly
into gels of higher viscosity; this may also explain our earlier obser-
vation that p-tau441 droplet fusion was inhibited as early as after
15 min (Fig 2D). When bleaching only a small portion of a droplet
to assess the molecular mobility in the droplets over time (Fig 4B),
we found that the immobile fraction of molecules in p-tau441
droplets steadily increased over time to 30%. After 60 min, almost
no FRAP was observed, which indicated the full polymerization of
p-tau441 in the droplets. The progressive loss of mobile tau mole-
cules at similar recovery rates (slope of fits) in the droplets can be
explained by a progressive polymerization process of tau in the
droplets, in which the amount of tau partitioning into the droplets
from the medium is very limited. In contrast, a gradual droplet
maturation with slowly decreasing partitioning of molecules from
the surrounding medium was, for example, described for the phase
transition of FUS (Shin et al, 2017). Our data suggest that tau
droplets rapidly transition from a liquid to a gel-like state. Interest-
ingly, the timing of full droplet maturation coincided with the
droplet deformation and aggregate occurrence observed for p-
tau441 (Fig 3D).
To describe the further transition toward tau aggregation, we
incubated p-tau441 droplet for extended times. After 1 day of
incubation at room temperature, p-tau441 droplets were stable
enough to be separated from the surrounding medium by centrifuga-
tion without losing their integrity and droplet shape, even after
resuspension in buffer without PEG (Fig 4C). This indicated the
maturation of the droplets into very stable gel-like spheres. Further-
more, tau protein accumulations could be found at the surface of
1-day-old p-tau441 droplets, which increased in number and size
over time (Fig 4D). After 10 days, most p-tau441 droplets had tran-
sitioned into large amorphous tau aggregates. To test whether these
tau aggregates contained amyloid-like b-sheet structures, we added
thioflavin-S (ThioS) to fresh p-tau441 preparations and observed the
fluorescence over time. ThioS is a dye that increases 10-fold in flu-
orescence upon binding to b-sheet structures, which is typically
used to stain amyloid-like tau protein aggregates in vivo and in vitro
(Santa-Marı´a et al, 2006). Immediately after mixing, ThioS parti-
tioned into p-tau441 droplets and showed only weak background
fluorescence after 1 h (Fig 4E), increased fluorescence indicating
b-sheets homogeneously distributed in some droplets after 4 h, and
condensed b-sheet rich aggregates on droplet surfaces after 24 h.
To further explore the rigidity of the mature tau droplets, we
employed atomic force microscopy (AFM). When imaging the
topography of 1-day-old p-tau441 droplets (in buffer in absence of
PEG) attached to a glass surface by force-distance curve-based
atomic force microcopy (Dufreˆne et al, 2013), we found a rather
high rigidity of the droplets, which by AFM resisted scanning
forces of > 250 pN, and that small tau aggregates protruded up to
0.5 lm as stiff structures from the droplet surface (Fig 4F,
Appendix Fig S3). To test whether the aggregates emerging from
p-tau441 droplets were on pathway with intracellular tau aggrega-
tion, we employed a cell assay for tau aggregation, in which HEK
cells expressing the FTD-mutant tau repeat domain (amino acids
243–372 of tau441) fused to CFP or YFP, TauRDP301S-CFP/YFP,
were treated with preformed aged p-tau441 droplets (Fig 4G). Cells
treated with 0.5 lM 3-day-old p-tau441 droplets showed
TauRDP301S aggregation already after 10 h, whereas control cells
that received no or non-LLPS soluble p-tau441 had no aggregates
at that time point.
The rapid transition of tau droplets into a gel-like phase, the
growing amount of stiff tau aggregates protruding from and filling
the droplets, as well as the progressive thioflavin-S fluorescence of
the droplets suggest that the conformation of tau in the droplets
changes with time toward a state resembling tau b-sheet aggregates
that are able to initiate intracellular tau aggregation. Together, and
similar to what has been described for FUS (Patel et al, 2015), phos-
pho-tau droplets undergo a maturation, whereby their fast (minutes)
increase in viscoelasticity efficiently prevents droplet coalescence
and initiates tau aggregation mostly on the droplet interface.
Conditions triggering tau aggregation also cause
droplet formation
The in vitro aggregation of tau into amyloid-like fibrils has been
manifold described by several authors, mostly with emphasis on
aggregation kinetics and aggregate structure (von Bergen et al,
2000; Tepper et al, 2014). Most of these aggregation studies have
been performed on non-phosphorylated recombinant tau (tau441),
which needs the addition of polyanionic co-factors such as heparin
(Goedert et al, 1996) or RNA (Kampers et al, 1996) in order to form
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aggregates. Because our data suggest that tau droplet formation may
be on pathway with tau aggregation, we tested whether conditions
triggering tau aggregation in vitro (pH 7.4, 50 mM salt, 20% (w/v)
heparin-16000 or 0.5 mg/ml cellular RNA) also lead to LLPS.
Surprisingly, we found that the addition of heparin or RNA to phos-
phorylated p-tau441 led to spontaneous formation of p-tau441
droplets, even in the absence of PEG (Fig 5A). We confirmed that
an extended incubation of p-tau441 with heparin (data not shown),
or even without (Tepper et al, 2014), supports the formation of fib-
rillary tau aggregates in vitro. Non-phosphorylated tau441 did not
show LLPS with heparin and RNA at the same low protein concen-
tration (2 lM) and in the same buffer conditions.
In the context of neurodegeneration, different FTD-associated
mutations in the tau gene can lead to the pathological aggregation
and deposition of tau in the brain. It has been shown in vitro that
some of these mutations enhance the nucleation and aggregation
rate and enable the aggregation of recombinant tau (from E. coli), to
some extent even in the absence of aggregation triggering co-factors
(Von Bergen et al, 2001). The molecular mechanism behind muta-
tion-induced tau aggregation is the strongly enhanced propensity for
b-structure of the hexapeptide motif in repeat 2 (Von Bergen et al,
2001). To test the hypothesis that FTD mutations causing tau
oligomerization and aggregation (Spillantini & Goedert, 2000) also
induce tau droplet formation as a precursor of aggregation, we
A
C
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Figure 5. Factors inducing tau aggregation also lead to tau LLPS.
A Aggregation co-factors heparin and RNA induce p-tau441 droplet formation in absence of crowding agent PEG.
B FTD mutations (ΔK280, P301L, P301S, A152T; green circles), which trigger tau oligomerization and aggregation, can induce tau droplets (white arrows) in tau441 in
absence of phosphorylation (2 lM protein, 10% PEG). In contrast, the anti-aggregation mutant ΔK280/PP (black circle), in which two proline insertions in R2 and R3
prohibit tau repeat domain aggregation, fails to trigger tau441 LLPS.
C Progressive aggregate formation from tauP301L droplets. Droplets of non-phosphorylated FTD-mutant tauP301L show progressive aggregate formation when
incubated at room temperature; clusters of tau protein aggregates connect individual droplets after 72 h, which increased at 96 h. ThioS fluorescence in tauP301L
droplets increased over time maybe due to viscosity increase, with less droplets but more ThioS-positive aggregates in the preparation after 96 h.
D Tau (TauHMW, black asterisk in Western blot) isolated from the high molecular weight (HMW) protein fraction of Alzheimer’s disease brain extract by affinity
chromatography (anti-human tau antibody HT7) initiates tau aggregation (white arrowheads) in HEK TauRDP301S-CFP/YFP cells.
E In the presence of molecular crowding (10% PEG), droplets and large aggregates can be observed in TauHMW preparations after 1–2 min.
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mixed different non-phosphorylated (from E. coli) pro-aggregation
mutant constructs of human full-length tau (tau441 P301L, tau441
P301S, tau441 ΔK280, tau441 A152T) with the crowding agent PEG
(Fig 5B). Surprisingly, all four pro-aggregation mutants induced
spontaneous droplet formation in the presence of molecular crowd-
ing, even in the absence of phosphorylation. Wild-type tau441, as
well as the anti-aggregation mutant tau441 ΔK280/PP, did not
undergo tau LLPS. In tau441 ΔK280/PP, the high b-propensity
caused by the ΔK280 mutation is reversed by two proline insertions
(I277P and I308P; Eckermann et al, 2007; Von Bergen et al, 2005).
Furthermore, and similar to p-tau441 droplets, mutant tau441P301L
droplets matured into aggregates and showed ThioS fluorescence
(Fig 5C).
From these data, it appears that tau phase separation in solution
may be a precursor of tau oligomerization and aggregation. Tau
mutations, as well as phosphorylation, may favor certain protein
conformations that enhance the b-strand interactions of the tau
repeat domain and in turn lead to LLPS and aggregation of tau.
Tau LLPS occurs in soluble, high molecular weight tau from
human AD brain
We previously showed that high molecular weight tau species,
which are hyperphosphorylated and presumably oligomeric in
nature, are bioactive for neuronal uptake and templated misfolding
(Takeda et al, 2015).
To further test the idea that disease-associated soluble tau is
related to LLPS and aggregation in AD, we isolated high molecular
weight tau (tauHMW) from AD brain lysate by size exclusion and
human tau (HT7 antibody) affinity chromatography. We found that
tauHMW was able to initiate tau aggregation in HEK TauRDP301S-
CFP/YFP cells (Holmes et al, 2014; Fig 5D), and, excitingly, showed
rapid (1–2 min) phase separation into droplets as well as aggrega-
tion when applying crowding conditions (10% PEG, Fig 5E).
Furthermore, by immunohistological labeling of phospho-tau in
post-mortem human brain tissue with mild AD pathology (Braak
stage III; Braak & Braak, 1995), we could find spherical phospho-tau
accumulations in hippocampal neurons (Fig EV6). These structures
were apparent in neurons with aberrant mild accumulation of p-tau
in the cell body but not in neurofibrillary tangles with thioflavin-S-
positive tau aggregates in the cell body; tau is normally excluded
from the cell body and present only in the axon. Notably, the verifi-
cation of a liquid or gel-like character of these spherical p-tau accu-
mulations in fixed tissue cannot be assessed using the typical
biophysical approaches like FRAP.
These observations are consistent with the hypothesis that
hyperphosphorylated tau in AD brain can undergo LLPS and aggre-
gation similar to what we observe for phospho-tau in vitro.
Discussion
While much research effort has been put toward determining tau
aggregate structure, aggregation kinetics (Von Bergen et al, 2005),
templated misfolding, and pathological toxicity of tau in the
diseased brain (Walker et al, 2013), two extremely important ques-
tions remain unclear: What triggers the very initial aggregation of
tau? And which mechanism underlies the switch from functional
soluble tau in a healthy neuron toward aberrantly pathologically
folded soluble tau, and fibrillary tau accumulating in NFTs? We
thought that the answer to this question may be found in two other
largely unknown aspects of tau biology: in its intrinsic disorder that
enables an ensemble of protein conformations and functions and in
the manifold PTMs of known and unknown function. Applying
multiple biophysical techniques including optical microscopy,
FRAP, AFM, multiphoton imaging, and electron microscopy, we
demonstrate that tau from multiple sources including recombinant
tau from SF9 cells (post-translationally modified tau) and E. coli
(unphosphorylated tau), as well as tau derived from human AD
brain, (i) can undergo LLPS and (ii) that tau LLPS droplets can
mature into aggregates, which may resemble the transition of
soluble tau into tau aggregates in neurodegenerative diseases.
Tau is an IDP with some transient secondary structure elements
of low propensity (Mukrasch et al, 2009). The rather short
(100 aa) semi-structured repeat domain bears some transient b-
sheet propensity, and its flanking proline-rich regions have been
identified as relevant for microtubule binding (MTB; Mukrasch
et al, 2007). The N-terminal half of tau stays unstructured when
projecting from MTs (Chen et al, 1992) and, in this context, a brush
of N-terminal domains on MTs may have mechanical relevance for
MT spacing (Chen et al, 1992). Other studies showed a role of the
N-terminal half of tau as binding site for kinases with SH3 domains,
such as Fyn and MARK (Reynolds et al, 2008). Phosphorylation of
tau in or next to the MT binding region, for example, by MARK,
reduces the affinity of tau to microtubules and causes its detach-
ment. Small mostly local changes in the structure of the P2 domain
and short peptide stretches in the repeat domain are thought to
cause the loss of tau’s binding capacity to assembled MTs
(Schwalbe et al, 2013). This process is considered a normal physio-
logical function of tau phosphorylation that is necessary to regulate
MT stability. However, hyperphosphorylation of tau often coexists
with tau aggregation in the diseased brain (Augustinack et al, 2002;
Iqbal et al, 2005), but the data for a causal relationship of tau aggre-
gation to tau phosphorylation are conflicting (Kumar et al, 2014;
Tepper et al, 2014; Simic et al, 2016). It has been reported though
that tau phosphorylation, for example, by GsK3b at multiple sites,
may precede the aggregation of tau in AD (Iqbal et al, 2005;
Stoothoff & Johnson, 2005; Mondrago´n-Rodrı´guez et al, 2008). And
recently, Time-Resolved ElectroSpray Ionization Mass Spectrometry
(TRESI-MS) suggested a molecular conformational shift of tau
toward a more amyloidogenic structure upon phosphorylation (Zhu
et al, 2015).
Here, we suggest that LLPS of phosphorylated or mutated tau
connects the somewhat enigmatic aspects of tau structural disorder,
phosphorylation, and disease-relevant aggregation initiation.
Hyperphosphorylation or pro-aggregation mutations, which
increase the b-sheet propensity in the repeat domain of tau and lead
to tau oligomerization and aggregation (Fischer et al, 2007), lead to
changes in the protein charge and conformation; these changes
appear to be crucial for the phase separation into droplets. For
example, the N-terminal half of tau (tau256), which is a priori zwit-
terionic and disordered, gains LLPS capacity when negative charges
are introduced by phosphorylation in the otherwise positively
charged proline-rich regions (P1 + P2), thereby neutralizing or
inverting the local charge excess. Similar to other reported LLPS
proteins (Brangwynne et al, 2015), electrostatic forces appear to be
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the drivers for the LLPS of the N-terminal half of tau because it can
be inhibited by increasing amounts of counter ions in solution.
In the case of full-length tau, the C-terminal half appears to intro-
duce additional hydrophobic interactions that are sensitive to
hexanediol, chaotropic salts, and protein unfolding by urea, but
largely insensitive to the concentration of “simple” mono- and biva-
lent ions provided by NaCl, KCl, or MgCl2 at high concentrations.
Furthermore, full-length and the C-terminal half of tau seem to have
the ability for LLPS at even lower protein concentrations (~1 lM)
and at extremely high ion concentrations. Whether this preference
for the droplet state is facilitated by hydrophobic interactions of the
short hexapeptide motifs with b-strand propensity, PHF6* and PHF6
in repeat 2 and 3 of tau, remains to be clarified using high-resolution
protein structural techniques. The spontaneous formation of ThioS-
positive and aggregation seeding tau aggregates in and on the
droplets supports this hypothesis. Furthermore, these findings are
consistent with the recently reported in vitro LLPS of the tau repeat
domain (Ambadipudi et al, 2017). Importantly, though, the contri-
bution of the N-terminal protein half to intracellular tau LLPS has to
be considered as another regulatory entity that could play an impor-
tant role for either the inhibition or stabilization of LLPS in the
brain.
Tau aggregates forming on the droplet surface may either consist
of and grow from free soluble tau molecules in the medium, or
develop due to physical properties of the droplet interface (e.g.,
surface tension, local tau concentration) that change the molecular
properties of tau at the droplet surface and locally increase its
propensity for aggregation; a similar effect is commonly utilized for
the crystallization of proteins out of solution (Zhang et al, 2012),
and by analogy, one could describe tau LLPS as an intracellular tau
crystallization process. This idea is supported by the observation
that concentrated tau solutions (> 50 lM) can spontaneously
undergo LLPS even in the absence of crowding agents. Interestingly,
the intracellular supersaturation of certain proteins—including tau
—has recently been linked to protein aggregation and neurodegener-
ative diseases (Ciryam et al, 2013, 2015).
The average concentration of 22 lM tau we detected in the
droplets is still far below the solubility limit of tau in E. coli and
purified tau in vitro. Therefore, in the cell, the association of tau
with other factors like polyanionic RNA, for example, in stress
granules (Vanderweyde et al, 2016), or the array of tubulin C-
termini on the microtubule surface (Ackmann et al, 2000) may
play an important role for tau LLPS; this idea is consistent with
our data showing tau LLPS induced by heparin and RNA, as well
as recent independent reports from three other laboratories
(Ambadipudi et al, 2017; Hernandez-Vega et al, 2017; Zhang et al,
2017).
The idea that LLPS and subsequent aggregation of tau is a fairly
rapid process under physiological conditions supports our previous
observation—by multiphoton in vivo real-time imaging—that the
formation of ThioS-positive tangles in neurons of tauP301L trans-
genic animals can occur in the course of hours (de Calignon et al,
2010). While LLPS may not be a strict prerequisite for aggregation,
since nucleation of tau aggregation has been reported, for example,
from a dimeric state (Wille et al, 1992), our hypothesis that tau
droplet formation can lead to tau aggregation is reinforced by the
finding that the tau aggregation co-factors heparin and RNA also
induce tau LLPS.
The maturation of liquid droplets into aggregates has been
reported for the ALS-associated proteins FUS (Patel et al, 2015),
TDP-43 (Schmidt & Rohatgi, 2016), and hnRNPA1 (Molliex et al,
2015). After LLPS, these proteins transition from an initial liquid
droplet state, through a gel-like state of high viscosity, to a final
stable aggregated form (Lin et al, 2015). In the case of FUS, the
liquid and gel state are reversible, whereas the transition into the
structurally (more) ordered aggregate state seems to be irreversible
(Patel et al, 2015). Tau, in contrast to FUS, does not have a clear
LCD. This structural difference may underlie the differences in
biophysical properties of the resultant droplets: Our FRAP data
and observations of droplet dynamics and growth can be inter-
preted in that tau droplets rapidly develop a “shell” of polymerized
tau, which prevents the exchange of tau molecules with the
surrounding medium and prohibits fusion and fission of the
droplets. The inside of the droplets appears to mature into a gel
phase more slowly. Upcoming in vitro studies using protein struc-
ture techniques will be necessary to provide insights into the
molecular details of the conformational transitions underlying tau’
liquid droplet-to-aggregate transition, and in vivo studies will need
to identify the processes that (dis)regulate tau LLPS in disease.
Nonetheless, the similarity of the current data on tau to previous
observations for FUS, hnRNPA1, and TDP43 indicates that the
protein biophysical process of LLPS may represent a common and
critical mechanism leading to ALS, AD, and FTD pathology.
Intracellular protein phase separation is used by the cell to
generate transient membrane-less assemblies that fulfill certain
functions; for example, stress granules assemble upon acute stress
and include certain RNA binding proteins, specific RNA, and other
molecules and solutes necessary to perform enhanced translation
of certain genes. Protein droplets can also function as small multi-
molecular machines that ensure efficient tubulin assembly
(Herna´ndez-Vega et al, 2017). We and others (Vanderweyde et al,
2016) observed droplet-like tau accumulation in neurons in vitro
and in vivo in the absence of tau aggregation. This indicates a
biological function of tau LLPS independent of aggregation and
also suggests that healthy neurons are able to maintain tau in a
potentially reversible droplet state. LLPS of full-length tau remains
highly efficient even at minor amounts of phosphorylation in
dephosphorylated tau (deP-tau441), and the addition of specific
phosphorylation by MARK2 that causes the detachment of tau
from microtubules seems sufficient to induce tau droplet forma-
tion. This further supports the idea that tau LLPS has a functional
role in neurons that is in conjunction with MTB and stabilization.
For example, the neuron could utilize local reversible tau LLPS to
create an instantly available pool of tau in “storage droplets” at
locations where microtubule polymerization is needed, such as
after axon injury, at branching points, or in the growth cone. In
fact, tau droplets can very efficiently induce microtubule assembly
(Hernandez-Vega et al, 2017). Besides microtubule-related func-
tions, tau droplets could interact with other polymer-gel entities in
the cell (e.g., the nuclear pore complex nucleoporins) or facilitate
the transport of molecules partitioning into the droplets. In fact,
the liquid phase separation of the unstructured N-terminal half of
tau may be related to some of the earlier observations showing a
polymer-brush-like projection of the N-termini from the surface of
microtubules (Vallee & Borisy, 1977; Gustke et al, 1994) as well as
from fibrillary tau aggregates (Wegmann et al, 2013). These
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polymer brushes can to some extent resemble two-dimensional
droplets with similar gel-like properties.
However, in an intraneuronal environment, an undefined mixture
of modified, truncated, and aggregated tau species with a plethora of
conformations coexist, and multiple binding partners of tau includ-
ing microtubules constantly change the local concentration of tau
available for LLPS. In such a scenario, the role and tuning of intracel-
lular phase transitions of tau is likely quite complicated.
Tau LLPS: an initial step toward tau aggregation
and neurodegeneration
Our data support the hypothesis that LLPS of phosphorylated tau is
a cell biologically relevant event, and strongly suggest that tau
droplet formation may resemble the initial step for aberrant tau
aggregation in the brain (Fig 6). We propose the following model
for the relevance of tau LLPS in tau aggregation: (i) Intraneuronal
tau, when phosphorylated (e.g., by MARK2 kinase) and detached
from microtubules, can undergo LLPS to form droplets that migrate
in the cytoplasm and along the axon/projections. The transition
from microtubule-bound and free soluble monomeric/dimeric tau
into tau droplets is facilitated by tau phosphorylation and the
normal intracellular molecular crowding. In a healthy neuron, LLPS
may be a normal process of containing, condensing, and providing
tau locally in the axon, and soluble and phase-separated tau exist in
an equilibrium in the cytosol. (ii) Hyperphosphorylation and pro-
aggregation mutations shift the equilibrium by favoring the droplet
state of phospho-tau, enhancing the subsequent maturation and
hardening, and seeding tau aggregation in and on tau droplets. It
remains to be clarified whether phosphorylation induced tau LLPS
occurs as cause or result of tau mislocalization into the somato-
dendritic compartment of neurons. (iii) The intraneuronal accumu-
lation of tau droplets and aggregated tau in the cell body (e.g., in
NFTs) causes not only long-term toxicity through ER stress and UPR
(Salminen et al, 2009), but it also depletes tau from the soluble pool
that is essential to maintain microtubule stability. Tau droplets
could also have other direct pathological consequences, for
example, through aberrant interaction with cellular organelles or
“absorption” of RNA molecules, which would impact protein
expression and homeostasis of the neuron. These effects can cause
high levels of short-term and long-term stress and eventually lead to
neuronal death.
In the diseased brain, however, we postulate that conditions
leading to aberrant tau hyperphosphorylation could favor the kinet-
ics of droplet formation and stabilization—such as AD and FTD
(Gong et al, 2005), elevated oxidative stress (Alavi Naini & Soussi-
Yanicostas, 2015), or traumatic brain injury (Blennow et al, 2012)—
may favor the droplet state of tau, lead to increased droplet stability
and droplet maturation, and eventually initiate tau aggregation. To
what extent specific phosphorylation sites join this interplay of LLPS
and aggregation remains to be explored.
Intracellular RNA (or other polyanions) may act as co-factor for
tau droplet stabilization and maturation, and further experiments
will have to address the specificity of RNA-induced tau LLPS (Zhang
et al, 2017). We believe that it will be of great importance to further
elucidate, (i) what are the cellular mechanisms that maintain the
homeostasis of tau and other liquid phase separation proteins to
prevent aggregation, (ii) whether neuronal subpopulations that are
vulnerable to tau aggregation (e.g., entorhinal and hippocampal
neurons in AD) also have unique tau LLPS characteristics, and (iii)
whether tau droplets are able to propagate across neuronal
networks and “seed” tau aggregation in connected brain areas.
Intracellular LLPS and the resulting functional membrane-less
organelles, which biophysically can be described as gels or poly-
electrolyte brushes, are emerging concepts in cell biology, which
are now implicated in manifold cellular functions and applications
(Li et al, 2012; Aumiller et al, 2014; Elbaum-Garfinkle et al, 2015;
Jiang et al, 2015; Aguzzi & Altmeyer, 2016; Mitrea et al, 2016;
Schmidt & Go¨rlich, 2016; Schmidt & Rohatgi, 2016). For research
in neurodegenerative diseases, in particular, the function and
misfunction of LLPS by involved proteins—such as tau, FUS,
TDP43, hnRNPA1, C9orf72 dipeptide repeats—introduces a novel
exciting concept that may provide a common underlying mecha-
nism in these diseases. Understanding the problem of initial and
Figure 6. Tau LLPS in neurons and potential consequences in tauopathies.
In healthy neurons (i), physiological tau phosphorylation detaches tau from microtubules and can lead to intraneuronal p-tau droplets. (ii) Disease-associated
hyperphosphorylation and aggregation triggering FTD mutations favor the droplet state of p-tau and lead to maturation of p-tau droplets into a viscous gel and subsequent
conversion into tau aggregates that can seed further tau aggregation. In the diseased neuron (iii), stable droplets and aggregates deplete p-tau from the pool available for
microtubule binding, which then can lead to uncontrolled microtubule fragmentation, the disruption of proteo-homeostasis, cell stress, and eventually neuronal death.
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progressive aggregation in AD and other protein aggregation
diseases (Eftekharzadeh et al, 2016) may support development of
novel therapeutic approaches.
Materials and Methods
Disorder, low complexity, and charge predictions
Disorder of human full-length tau [2N4R, 441 amino acids (aa)] was
predicted using PONDR (http://www.pondr.com/) and disEMBL
(http://dis.embl.de/), low complexity was predicted using
CAST (http://dis.embl.de/) and SEG (http://mendel.imp.ac.at/
METHODS/seg.server.html), and the single amino acid as well as
the average (sliding window of 6 aa) charge distribution along the
primary sequence was analyzed using EMBOSS (http://www.bioinf
ormatics.nl/cgi-bin/emboss/charge).
Calculating the intraneuronal tau concentration in the
human brain
In order to estimate the concentration of tau in neurons in the human
brain, we (i) determined the number of neurons per volume in
human frontal lobe cortex by stereology, then (ii) determined the
amount of tau in the same cortical volume by human tau specific
ELISA, and (iii) estimated the neuronal volume as either the neuronal
cell body volume using previously published data (pyramidal neuron
cell body diameter 20 lm = smallest possible volume; a scenario
that would represent tau missorting in Alzheimer’s disease), or as the
space occupied by a neuron in the cortex (average cortical volume
occupied per entire neuron = largest possible volume). As a result,
we calculate an average intraneuronal tau concentration in the range
between 1.68  0.68 lM and 6.84  0.42 lM in human frontal
cortex axons. Because of a protein extraction efficiency of 23%,
these values are likely underestimating the actual tau concentration
by a factor of 4–5. Further details are presented in Appendix Supple-
mentary Methods.
Recombinant GFP-tau expression and purification in
Escherichia coli
Tau expression was carried out as previously reported (Barghorn
et al, 2005). pET-29b tau plasmid containing full-length human
tau tau441 (2N4R), tau mutants [tau441_E17; tau441_DK280;
tau441_DK280/PP (Eckermann et al, 2007); tau441_P301L;
tau441_P301S; and tau441_A152T (Pir et al, 2016)], or tau256 (N-
terminal 256 amino acids of tau441) was transfected into E. coli
BL21. For protein expression, bacteria were grown in suspension
at 37°C to an optical density of 0.6 and expression was induced by
adding 1 mM isopropyl beta-d-thiogalactopyranoside (IPTG) for
3.5 h. Cells were pelleted by centrifugation at 6,000 g for 20 min
at 4°C and cell pellets resuspended in resuspension buffer [20 mM
MES, 400 mM NaCl, 0.2 mM MgCl2, 5 mM DTT, protease inhibitor
cocktail (Complete, Roche) pH 6.8]. Cells were lysed by sonication
on ice for four times 15 s on/30 s off and then boiled for 20 min.
Cell debris and denatured proteins were pelleted by centrifugation
at 100,000 g for 1 h at 4°C. and the supernatant was dialyzed
against 1 l of ion exchange loading buffer [20 mM MES, 50 mM
NaCl, 1 mM MgC12, 2 mM DTT, 1 mM PMSF, pH 6.8]. Tau
proteins were purified using cation exchange chromatography
(column HiPrep SP FF) and size exclusion chromatography (SEC)
(column Superdex G200) using an A¨KTA chromatography setup
(GE Healthcare).
Recombinant tau expression and purification from Sf9
The proteins p-tau441, p-tauCt, and p-tau256 were expressed in Sf9
cells and purified as described before (Tepper et al, 2014). In short,
the cells were infected with the recombinant virus (pVLhtau40) and
incubated for 3 days. The cell lysate was heated and the heat-stable
tau proteins purified by size exclusion column Superdex G200 (GE
Healthcare). Tau phosphorylated in Sf9 cells and then dephosphory-
lated (deP-tau441) was obtained as previously described (Mair et al,
2016) by incubating p-tau-441 (100 ll; 5 lM) with 10 U of
alkaline phosphatase FAST-AP (Thermofisher) for 20 h at 37°C in
FAST-AP-Buffer. The enzyme was removed afterward by high salt
treatment (incubating 10 min at 70°C, 5 M NaCl and 5 mM DTT,
followed by 30 min centrifugation at 66,000 g). The protein was
recovered from the supernatant by desalting (ZebaTM Desalt spin
columns; Thermo Fischer). In vitro MARK2 phosphorylation was
achieved by incubating tau441 with purified MARK2/T208V in pres-
ence of 1 mM ATP for 2 h at 37°C (Timm et al, 2003). The enzyme
was removed by heat treatment and desalting as for deP-tau441.
Phosphorylation was verified by SDS–PAGE of 0.4 lg tau protein
per lane and Western blot analysis with rabbit anti-human tau
(DAKO), mouse anti-phospho-tau pS262/pS356 (12e8), and mouse
anti-phospho-tau p396/pS404 (PHF1, provided by Peter Davis).
Phosphorylation sites previously reported in p-tau441 by mass
spectrometry (Mair et al, 2016) were verified by Western blot with
a set of antibodies against the reported sites (Fig EV1G,
Appendix Table S4).
Fluorescent labeling of p-tau
p-tau256 and p-tau441 were labeled with Dylight488-NHS ester
(dl488, LifeTechnologies). For highest yield of N-terminal labeling,
the amino-reactive dye was dissolved in DMSO and 5 ll was added
to 100 lg p-tau256 protein in PBS at pH 7.4 for 1 h at room temper-
ature. Excess dye was removed by dialysis (SlideLizer MWCO
10 kDa, Pierce) against (10 mM HEPES buffer, 20 mM NaCl, pH
7.4) at 4°C overnight. p-tau441-a568 was produced by labeling
p-tau441 using thiol-reactive AlexaFluor568 C5 maleimide (Life
Technologies) according to the manual. The labeling reaction was
carried out at RT for 3 h, and excess dye was removed with a NAP-
5 column (GE Healthcare). In this protein, the dye can bind cova-
lently to the two native cysteines (Cys291 and/or Cys322). In the
used protein preparation, a mean [dye: protein] ratio of ~1.5 was
achieved.
The concentration of p-tau441-a568 in the droplets was estimated
from confocal images (533 nm laser line, pinhole of 3 lm). Mean
droplet and background fluorescence intensity were measured from
images collected at the same laser and PMT settings by measuring
mean pixel intensity in ROIs using ImageJ. Fluorescence intensity
was compared against images recorded in absence of LLPS
from p-tau441-a568 solutions of known protein concentration.
Absorbance spectrum changes of free Alexa568 in presence of
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crowding agent PEG were tested using a Nanodrop and fluorescence
intensity of confocal images.
Formation of tau droplets with crowding agents and polyanions
For each tested condition, the concentration of tau proteins, crowd-
ing agents [PEG-8000 or Ficoll-400 or dextran-70 (Sigma)], and dif-
ferent salts [NaCl, NaSCN, KCl, MgCa2, (NH4)2SO4, guanidinium
hydrochloride (GdmHCl), urea (all chemicals from Sigma)] was
adjusted using 10 mM HEPES pH 7.4, 10 mM citrate pH 3.0, or
10 mM Tris Base pH 9.5. All buffer solutions were degassed. Alter-
natively, p-tau441 LLPS was initiated by addition of RNA (total
human brain RNA (0.5 lg/ll, Agilent Technologies) or 20% (w/v)
heparin (MW  16,000 Da, Sigma). Control proteins bovine serum
albumin (Sigma) and GFP (Abcam) were solved and then sonicated
(2 × 10 s at 10% amplitude on ice) in HEPES buffer, and residual
aggregates were removed by centrifugation at 21,000 g at 4°C. To
visualize the droplets, 3–6 ll of the mix was immediately deposited
onto a clean microscope slide and covered to avoid evaporation, or
on a Matek glass-bottom dish. Imaging was performed on a Zeiss
Axio-Imager microscope equipped with a CoolSnap camera, or with
an Olympus FLUOVIEW confocal microscope.
To determine the droplet growth of different phospho-tau
constructs, brightfield confocal z-stacks (2 lm confocal plane thick-
ness, 20–40 lm total z-stack thickness) of free-floating droplets
were recorded in the middle of the deposited solution (far above the
supporting glass surface) using an Olympus FLUOVIEW confocal
microscope equipped with a 63× objective. Z-stacks were recorded
for each tau construct at different time points after addition of 10%
PEG to 5 lM tau protein, and each experiment was repeated twice.
To determine the droplet volume, only p-tau droplets in the focal
plane (identified as having a thin, low-contrast droplet border) were
considered. Circles were fitted on their phase border, and the
droplet volume was calculated from measured circle areas in ImageJ
assuming spherical droplet shape. Data are represented as mean
droplet volume  s.d.
To visualize crowding agent distribution, p-tau droplets were
initiated with 9% unlabeled dextran-70 kDa and 1% dextran-3 kDa-
Cascade blue, dextran-20 kDa-FITC, or dextran-70 kDa-FITC. To
label tau droplets with dyes, we added 50 lM ThioS (Sigma),
100 nM methylene blue (GIBCO), or 100 nM viscous aqua (URSA
Bioscience) to freshly prepared p-tau droplets.
Transmission electron microscopy
5 ll tau droplet preparations (final tau concentration 2–20 lM,
10% PEG) was directly adsorbed onto carbon-coated EM grids (Elec-
tron Microscopy Science) for 15–20 min or fixed in solution by
adding 2% (w/v) paraformaldehyde (PFA) before adsorption.
Excess protein was removed by placing EM grids two times on drops
of fresh buffer (10 mM HEPES, 20 mM NaCl, pH 7.4), and post-fixa-
tion was done in fresh 1% (w/vol) glutaraldehyde in PBS for 3 min
followed by excessive washing in water. The samples were nega-
tively stained by incubation in 2% (w/vol) uranyl-acetate in water
two times for 8 min each time, followed by brief washing in water
and 10 min drying at 23°C. For immunogold labeling, polyclonal
rabbit anti-tau antibody KJ9A (DAKO, antibody raised against the
C-terminal half of human 4R tau) coupled with 5 nm gold particles
was added to preformed tau droplets prior to their deposition on the
EM grids. Specimens were imaged by TEM (JEOL, JEM-1011, or
JEM-2200FS).
Fluorescence recovery after photobleaching
fluorescence recovery after photobleaching (FRAP) experiments
were performed on in vitro droplets formed by [p-tau256 + p-
tau256-Dylight488 (9 + 1)] or [p-tau441 + p-tau441-Dylight488
(9 + 1)] using the 488 nm laser line, respectively, of a confocal Zeiss
510 microscope equipped with a 63× 1.2 NA C-APO-plan Neofluo
objective (Carl Zeiss). For each droplet, either the whole droplet or
a spot (diameter of 1 lm) was bleached at 100% transmission
(50 mW laser power) for 2–10 s, and post-bleach time-lapse
images were collected (1 s frame rate, 150 frames) and analyzed
with MATLAB. For each time-lapse image, the mean fluorescence
intensities of the same three regions were recorded (ROI1 = photo-
bleached region, ROI2 = unbleached region in same droplet to
correct for the overall photobleaching, and ROI3 = background
signal outside of droplet was subtracted from both ROI1 and ROI2
intensities). The recovery time constant was derived from a single
exponential fit of the corrected fluorescence intensities plotted
versus time using GraphPad Prism 7. For FRAP of p-tau256-
Dylight488 droplets in presence of RNA-Cy3, both 488 and 543 nm
laser lines were used for simultaneous photobleaching of Dylight488
and Cy3 fluorophores.
Intracellular FRAP of GFP-tau441 was performed on primary
cortical mouse neuron expressing GFP-tau441 or GFP-polyQ(79)
(Htt exon-1 with 79Q) for 24 h or on HEK TauRDP301S-CFP/YFP
cells after tau aggregation initiation using tau transgenic mouse
brain lysate (details see below). For each droplet or aggregate, the
bleach ROI1 was restricted to the feature of interest and bleached at
100% transmission (50 mW laser power) for 10 s, and post-bleach
time-lapse images were collected (15 s frame rate, 25–30 frames)
and analyzed with ImageJ. Reference ROIs were defined in the
cytosol of the same cell (ROI2) and outside of the cell (ROI3).
Cloning of GFP-tau
To generate the GFP-tau441 plasmid, human full-length tau441
(2N4R) was cloned into the pMAXFP.Green (GFP) vector (Amaxa).
GFP-tau256 was generated by adding restriction sites for KpnI and
BamHI (New England Biolabs) at the 50 and 30 end, respectively, of
tau256, followed by ligation into the pMAXFP.Green vector after it
was digested with KpnI and BamHI. tau256 itself was generated by
placing a stop codon in tau441.
Cell cultures, transfection, and droplet formation
N2a cells were cultured under standard cell culture conditions in
Opti-MEM (Thermofisher) supplemented with 10% fetal bovine
serum (FBS) and 1% antibiotics penicillin/streptomycin. To express
GFP-tau or GFP only, cells were transfected with plasmid DNA using
Lipofectamine 2000 (Thermofisher) according to the manufacturer’s
instructions and imaged 3–24 h post-transfection. Note that GFP-tau
droplets were only visible in cells expressing low to medium levels
of GFP-tau and before the cell body was filled with bright GFP fluo-
rescence. Primary cortical mouse neurons were prepared from
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cerebral cortices of CD1 mouse embryos (E14–15, Charles River
Laboratories) using a papain dissociation system (Worthington
Biochemical Corporation) as described previously (Takeda et al,
2015). In brief, cortices were dissected out and mechanically disso-
ciated in Neurobasal medium (Thermofisher) supplemented with
10% FBS, 2 mM Glutamax, 100 U/ml penicillin, and 100 g/ml
streptomycin and plated in the same medium at a density of 0.6*105
cells per well of a NuncTM Lab-TekTM II Chambered Coverglass or in
Chamber 1 of microfluidic devices (see below); all neuron culture
dishes were previously coated with poly-D-lysine (50 mg/ml 1,
Sigma). Cultures were maintained at 37°C with 5% CO2 in Neuro-
basal medium with 2% (v/v) B27 nutrient, 2 mM Glutamax, and
antibiotics as above. On day 7, neurons were transfected using Lipo-
fectamine 2000. Tau droplet formation in N2a and neurons was
recorded 24 h post-transfection. Imaging of live or PFA-fixed cells
was performed on a confocal Zeiss 510 inverted microscope
equipped with a 63× 1.2 NA C-APO-plan Neofluo objective (Carl
Zeiss) and an incubation chamber to maintain culture conditions
(37°C, 5% CO2).
All animal work was performed in compliance with the MGH
and NIH.
Immunofluorescence labeling and microscopy
For immunofluorescent labeling, cells were rinsed once with warm
PBS and immediately fixed in 4% PFA in PBS for 10 min at RT.
After washing twice with Tris-buffered saline (TBS), cells were
permeabilized using 0.1% Triton X-100 in TBS for 20 min at RT,
blocked in 3–5% normal goat serum (NGS) in PBS for 1 h at room
temperature, and then incubated with primary antibodies (rabbit
anti-Lamp1, Abcam; rabbit anti Rab5, SantaCruz; rabbit anti KDEL,
Abcam; dilution 1:250 in 3% NGS/PBS) overnight at 4°C. After
washing three times with TBS, secondary antibodies were applied
for 1.5 h at room temperature (diluted 1:1,000 in 3% NGS/PBS),
then washed off three times with PBS, and mounted with anti-fade
mounting media containing DAPI. Human paraffin-embedded brain
slices prepared from an old individual (88 years old, female, mild
neurofibrillary tangle pathology in cortex and hippocampus, Braak
stage III) were first immunolabeled as described above using a mix
of rabbit phospho-tau antibodies (rabbit anti pT181, pS199, pT205,
pT231, pS409; Life Technologies) and then incubated for 20 min
with 0.1% (w/v) Sudan Black solution. Neurofibrillary tangles were
labeled using 0.025% thioflavin-S in 50% ethanol for 8 min
followed by washing with 80% ethanol for 2 min and three times
water. Imaging was performed on a Zeiss Axiovert200.
Size exclusion chromatography and affinity chromatography of
human brain lysates
PBS extracts of AD and control brains were Dounce homogenized
(30 strokes, GKH motor drive (Glas-Col), 50% speed), spun down at
3,000 g to remove nuclei, and followed by 10,000 g to remove
debris and large organelles. After filtering through a 0.2-mm
membrane, 1 ml brain extract (3–4 mg total protein) was loaded
onto a 12 × 1.5 cm Superdex200 prep grade SEC column (GE
Healthcare) and 1.4 ml fractions were collected at a flow rate of
0.125 ml/min. Collected fractions were frozen immediately at
20°C and later analyzed for protein (BCA assay) and human tau
content by ELISA (Tau5/HT7 antibody, Calbiochem 5778010, Invit-
rogen MN1000B). HMW protein SEC fractions 2 + 3 from were
pooled and repeatedly loaded (for 5 min at RT each load) onto a
Separopore 4B-CL (bioWORLD) column coupled to mouse anti-
human tau HT7 (Thermofisher MN1000). Following three 2 ml
washes, HMW tau was eluted using 1 ml of 3 M MgCl at pH 4.5.
The eluted sample was dialyzed (3,500 kDa MWCO, Slide-A-Lyzer,
Thermo) and then concentrated 10-fold using 3,000 kDa MWCO
centrifugal filters (Amicon Ultra, Millipore). TauHMW was analyzed
by standard SDS–PAGE followed by Coomassie (SimplyBlue, Invit-
rogen) and silver staining (Pierce 24612, Thermo Scientific), by
Tau5/HT7 ELISA, and by Western blot with anti-total tau antibody
(rabbit anti-human tau, DAKO). Protease inhibitor cocktail (Cell
Signaling Technologies) was added to all PBS used, and extracts,
buffers, and columns were kept at 4°C. Low protein binding tubes
(Richell) were used whenever tau was present.
HEK cell tau aggregation assay
HEK293 cells stably expressing the repeat domain (TauRD, aa243-
372) of human mutant Tau441P301S tagged with CFP and YFP
(HEK TauRDP301S-CFP/YFP (Holmes et al, 2014)] were treated
with preformed p-tau441 droplets, soluble p-tau441 [0.5 lM tau,
0.8% lipofectamine (LifeTechnologies)], or TauHMW from human
AD brain lysates (20 ng tau, 0.8% lipofectamine). Treating these
cells with tau material competent of seeding tau aggregation results
in intracellular aggregation of TauRDP301S-CFP/YF, which can be
detected as small fluorescent FRET-positive protein aggregates. Cells
were imaged to evaluate the presence of aggregates after 10 or 48 h
upon treatment with the tau samples. For FRAP of tau aggregates in
HEK TauRDP301S-CFP/YFP, aggregation was initiated by adding
brain lysate (5 lg/ll total protein) from 9-month-old human
tauP301L transgenic mice [rTg4510 line (Santacruz et al, 2005)] to
the culture medium in the presence of 1% lipofectamine 2000
(Thermofisher) for 12 h.
Western blot analysis of cell and brain lysates and
recombinant p-tau441
Intracellular phosphorylation of tau was tested by Western blot
analysis of cell lysates from murine neuroblastoma N2a cells and
from primary cortical mouse neurons expressing GFP-tau256 or
GFP-tau441. After separation by SDS–PAGE in MES running
buffer and blotting onto nitrocellulose membrane, phospho-tau
in cell lysates was detected by incubating with primary antibod-
ies (mouse anti-human tau Tau13, Biolegends, 1:1,000; mouse
PHF-1 (anti-pS394/pS404, Peter Davis, 1:1,000; rabbit anti p-tau
mix (anti-pS199, anti-pT231, anti-pT205, Life Technologies,
1:1,000) overnight at 4°C, followed by incubation with infrared
(IR) dye-labeled secondary anti-mouse680 and anti-rabbit800
antibodies (Licor) for 1 h at RT. Recombinant tau proteins which
were tested for phosphorylation blots were imaged using a Licor
IR scanner.
In vivo two-photon imaging of mouse cortex
An adeno-associated virus (AAV) vector encoding the fluorescent
photoconvertible protein Dendra2 N-terminally fused to human
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full-length tau (2N4R), AAV8-CBA-Dendra-tau441, was generated
by cloning Dendra2 (Addgene) into the AAV CBA-tau441-WPRE
vector. AAVs encoding Dendra2-tau441 or GFP were stereotactically
injected into opposite hemispheres of wild-type mice (C57, black6,
Jackson Laboratory) for expression in layer 2/3 of the somatosen-
sory cortex (from lambda: 2.0 mm anterior/posterior, 2.0 mm
lateral, 0.6 mm dorsal/ventral). Three weeks after injection, a
cranial window was implanted by replacing a circular piece (6 mm
diameter) of skull above the injection coordinates with a glass
coverslip that was secured in place using dental cement and Crazy
Glue.
Two-photon fluorescence of unconverted Dendra2 was excited at
800 nm using a mode-locked Ti: sapphire laser (MaiTai; Spectra
Physics) and detected in the green channel (GFP emission). Image
Z-stacks were recorded in anaesthetized mice using a multiphoton
imaging system (Fluoview1000; Olympus; laser power, ≤ 50 mW)
with a water immersion objective (25×, NA = 1.05; Olympus).
Image processing was performed in ImageJ (National Institutes of
Health).
Atomic force microscopy of droplet surface
AFM images were recorded in PBS with a BioScope Resolve micro-
scope (Bruker) equipped with a 100 × 100 × 15 lm (x, y, z) piezo-
electric scanner. AFM cantilevers (PFQNM-LC from Bruker) had
nominal spring constants of 0.08 N/m, had resonance frequencies
of 60 kHz in buffer, and carried a SiO2 stylus with a nominal apex
radius of 65 nm. The cantilevers were functionalized with NH2
groups, then coated with heterobifunctionalized 27-unit long PEG
linkers (NHS-PEG27-maleimide), and quenched with b-mercap-
toethanol to lower the adhesion to imaged surfaces (Wildling et al,
2012). Images were taken using force-distance curve-based AFM
(Dufreˆne et al, 2013; PeakForce mode, Bruker) in buffer solution
(20 mM Hepes, 50 mM NaCl, pH 7.4) at room temperature. Imaging
parameters included a scan rate of 0.4–0.6 Hz, sampling rate of
2 kHz, maximum imaging force of 200–300 pN and oscillating the
AFM stylus at a vertical amplitude of 400 nm. For each topo-
graphic pixel (512 × 512 px), the force-feedback loop limited the
imaging force by regulating the stylus sample distance, which was
taken to reconstruct the AFM topography. Topographs were flat-
tened using built-in processing tools. Cross-sectional profiles were
analyzed using ImageJ v1.43 (National Institutes of Health) and
plotted using GraphPad Prism 7.
Expanded View for this article is available online.
Acknowledgements
We thank João Pereira for help with live-cell imaging, Jacek Biernat and Lars
Krueger for helpful discussion, and the DeFiglia Lab for providing the GFP-
polyQ plasmid. B.T.H. receives funding from Massachusetts Alzheimer Disease
Research Center P50AG005134, J.P.T. receives funding from HHMI and NINDS
R35NS097974, and E.M. and K.T were supported by DZNE and MPG.
Author contributions
SW, BE, and KT designed and performed most experiments. BTH, JPT, EM, DM,
and AAH helped with manuscript discussion. KMZ, REB, SD, PRL, DMK, TK, CC,
CV, ADR, AMM, and AHV helped with experiments. ZF and SD helped with
vector design and production. SW, BE, and BTH wrote the manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
References
Abbott CE (1977) A survey of waterdrop interaction experiments. Rev Geophys
15: 363 – 374
Ackmann M, Wiech H, Mandelkow E (2000) Nonsaturable binding indicates
clustering of Tau on the microtubule surface in a paired helical filament-
like conformation. J Biol Chem 275: 30335 – 30343
Aguzzi A, Altmeyer M (2016) Phase separation: linking cellular
compartmentalization to disease. Trends Cell Biol 26: 547 – 558
Alavi Naini SM, Soussi-Yanicostas N (2015) Tau hyperphosphorylation and
oxidative stress, a critical vicious circle in neurodegenerative tauopathies?
Oxid Med Cell Longev 2015: 151979
Ambadipudi S, Biernat J, Riedel D, Mandelkow E, Zweckstetter M (2017)
Liquid–liquid phase separation of the microtubule-binding repeats of the
Alzheimer-related protein Tau. Nat Commun 8: 275
Arai T, Guo JP, McGeer PL (2005) Proteolysis of non-phosphorylated and
phosphorylated tau by thrombin. J Biol Chem 280: 5145 – 5153
Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002) Specific tau
phosphorylation sites correlate with severity of neuronal cytopathology in
Alzheimer’s disease. Acta Neuropathol 103: 26 – 35
Aumiller WM, Davis BW, Keating CD (2014) Phase separation as a possible
means of nuclear compartmentalization. Int Rev Cell Mol Biol 307:
109 – 149
Barghorn S, Biernat J, Mandelkow E (2005) Purification of recombinant tau
protein and preparation of Alzheimer-paired helical filaments in vitro.
Methods Mol Biol 299: 35 – 51
von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E
(2000) Assembly of tau protein into Alzheimer paired helical filaments
depends on a local sequence motif ((306)VQIVYK(311)) forming beta
structure. Proc Natl Acad Sci USA 97: 5129 – 5134
Berry J, Weber SC, Vaidya N, Haataja M, Brangwynne CP (2015) RNA
transcription modulates phase transition-driven nuclear body assembly.
Proc Natl Acad Sci USA 112: E5237 – E5245
Blennow K, Hardy J, Zetterberg H (2012) The neuropathology and
neurobiology of traumatic brain injury. Neuron 76: 886 – 899
Braak H, Braak E (1995) Staging of Alzheimer’s disease-related neurofibrillary
changes. Neurobiol Aging 16: 271 – 278
Brangwynne CP, Eckmann CR, Courson DS, Rybarska A, Hoege C,
Gharakhani J, Julicher F, Hyman AA, Julicher F, Hyman A, Cherkasov V,
Hofmann S, Druffel-Augustin S, Mogk A, Tyedmers J, Stoecklin G, Bukau
B, Han T, Kato M, Xie S et al (2009) Germline P granules are liquid
droplets that localize by controlled dissolution/condensation. Science
324: 1729 – 1732
Brangwynne CP, Tompa P, Pappu RV (2015) Polymer physics of intracellular
phase transitions. Nat Phys 11: 899 – 904
Burke KA, Janke AM, Rhine CL, Fawzi NL (2015) Residue-by-residue view of
in vitro FUS granules that bind the C-terminal domain of RNA polymerase
II. Mol Cell 60: 231 – 241
de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL,
Hyman BT (2010) Caspase activation precedes and leads to tangles.
Nature 464: 1201 – 1204
Carmel G, Mager EM, Binder LI, Kuret J (1996) The structural basis of
monoclonal antibody Alz50’s selectivity for Alzheimer’s disease pathology. J
Biol Chem 271: 32789 – 32795
18 of 21 The EMBO Journal 37: e98049 | 2018 ª 2018 The Authors
The EMBO Journal Tau droplets transition into aggregates Susanne Wegmann et al
Chen J, Kanai Y, Cowan NJ, Hirokawa N (1992) Projection domains of MAP2
and tau determine spacings between microtubules in dendrites and
axons. Nature 360: 674 – 677
Ciryam P, Tartaglia GG, Morimoto RI, Dobson CM, Vendruscolo M (2013)
Widespread aggregation and neurodegenerative diseases are associated
with supersaturated proteins. Cell Rep 5: 781 – 790
Ciryam P, Kundra R, Morimoto RI, Dobson CM, Vendruscolo M (2015)
Supersaturation is a major driving force for protein aggregation in
neurodegenerative diseases. Trends Pharmacol Sci 36: 72 – 77
Conicella AE, Zerze GH, Mittal J, Fawzi NL (2016) ALS mutations disrupt
phase separation mediated by a-helical structure in the TDP-43 low-
complexity C-terminal domain. Structure 24: 1537 – 1549
Drubin DG, Feinstein SC, Shooter EM, Kirschner MW (1985) Nerve growth
factor-induced neurite outgrowth in PC12 cells involves the coordinate
induction of microtubule assembly and assembly-promoting factors. J Cell
Biol 101: 1799 – 1807
Dufrêne YF, Martínez-Martín D, Medalsy I, Alsteens D, Müller DJ (2013)
Multiparametric imaging of biological systems by force-distance curve–
based AFM. Nat Methods 10: 847 – 854
Eckermann K, Mocanu MM, Khlistunova I, Biernat J, Nissen A, Hofmann A,
Schönig K, Bujard H, Haemisch A, Mandelkow E, Zhou L, Rune G,
Mandelkow EM (2007) The b-propensity of tau determines aggregation
and synaptic loss in inducible mouse models of tauopathy. J Biol Chem
282: 31755 – 31765
Eftekharzadeh B, Hyman BT, Wegmann S (2016) Structural studies on the
mechanism of protein aggregation in age related neurodegenerative
diseases. Mech Ageing Dev 156: 1 – 13
Elbaum-Garfinkle S, Kim Y, Szczepaniak K, Chen CC-H, Eckmann CR, Myong S,
Brangwynne CP (2015) The disordered P granule protein LAF-1 drives
phase separation into droplets with tunable viscosity and dynamics. Proc
Natl Acad Sci USA 112: 7189 – 7194
Fischer D, Mukrasch MD, Von Bergen M, Klos-Witkowska A, Biemat J,
Griesinger C, Mandelkow E, Zweckstetter M (2007) Structural and
microtubule binding properties of tau mutants of frontotemporal
dementias. Biochemistry 46: 2574 – 2582
Fulton AB (1982) How crowded is the cytoplasm? Cell 30: 345 – 347
Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA
(1996) Assembly of microtubule-associated protein tau into Alzheimer-like
filaments induced by sulphated glycosaminoglycans. Nature 383: 550 – 553
Gong C-X, Liu F, Grundke-Iqbal I, Iqbal K (2005) Post-translational
modifications of tau protein in Alzheimer’s disease. J Neural Transm 112:
813 – 838
Goode BL, Denis PE, Panda D, Radeke MJ, Miller HP, Wilson L, Feinstein SC
(1997) Functional interactions between the proline-rich and repeat regions
of tau enhance microtubule binding and assembly. Mol Biol Cell 8:
353 – 365
Gu H, Duits MHG, Mugele F (2011) Droplets formation and merging in two-
phase flow microfluidics. Int J Mol Sci 12: 2572 – 2597
Guillén-Boixet J, Buzon V, Salvatella X, Méndez R (2016) CPEB4 is regulated
during cell cycle by ERK2/Cdk1-mediated phosphorylation and its
assembly into liquid-like droplets. Elife 5: e19298
Gustke N, Trinczek B, Biernat J, Mandelkow EM, Mandelkow E (1994)
Domains of tau protein and interactions with microtubules. Biochemistry
33: 9511 – 9522
Hernández-Vega A, Braun M, Scharrel L, Jahnel M, Wegmann S, Hyman BT,
Alberti S, Diez S, Hyman AA (2017) Local nucleation of microtubule
bundles through tubulin concentration into a condensed tau phase. Cell
Rep 20: 2304 – 2312
Hiller G, Weber K (1978) Radioimmunoassay for tubulin: a quantitative
comparison of the tubulin content of different established tissue culture
cells and tissues. Cell 14: 795 – 804
Hofmeister F (1888) Zur Lehre von der Wirkung der Salze. Arch Exp Pathol
Pharmakol 25: 1 – 30
Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC,
Belaygorod L, Cairns NJ, Holtzman DM, Diamond MI (2014) Proteopathic
tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci USA 111:
E4376 – E4385
Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R,
Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D (2010) Tau
mislocalization to dendritic spines mediates synaptic dysfunction
independently of neurodegeneration. Neuron 68: 1067 – 1081
Hyman AA, Weber CA, Jülicher F (2014) Liquid-liquid phase separation in
biology. Annu Rev Cell Dev Biol 30: 39 – 58
Iqbal K, Del C, Alonso A, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon
S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I (2005) Tau
pathology in Alzheimer disease and other tauopathies. Biochim Biophys
Acta 1739: 198 – 210
Jeganathan S, Von Bergen M, Brutlach H, Steinhoff HJ, Mandelkow E (2006)
Global hairpin folding of tau in solution. Biochemistry 45:
2283 – 2293
Jiang H, Wang S, Huang Y, He X, Cui H, Zhu X, Zheng Y (2015) Phase
transition of spindle-associated protein regulate spindle apparatus
assembly. Cell 163: 108 – 122
Johnson GV, Stoothoff WH (2004) Tau phosphorylation in neuronal cell
function and dysfunction. J Cell Sci 117: 5721 – 5729
Kampers T, Friedhoff P, Biernat J, Mandelkow EM, Mandelkow E (1996) RNA
stimulates aggregation of microtubule-associated protein tau into
Alzheimer-like paired helical filaments. FEBS Lett 399: 344 – 349
Kato M, Han TW, Xie S, Shi K, Du X, Wu LC, Mirzaei H, Goldsmith EJ,
Longgood J, Pei J, Grishin NV, Frantz DE, Schneider JW, Chen S, Li L,
Sawaya MR, Eisenberg D, Tycko R, McKnight SL (2012) Cell-free formation
of RNA granules: low complexity sequence domains form dynamic fibers
within hydrogels. Cell 149: 753 – 767
King OD, Gitler AD, Shorter J (2012) The tip of the iceberg: RNA-binding
proteins with prion-like domains in neurodegenerative disease. Brain Res
1462: 61 – 80
Kroschwald S, Maharana S, Mateju D, Malinovska L, Nüske E, Poser I, Richter
D, Alberti S (2015) Promiscuous interactions and protein disaggregases
determine the material state of stress-inducible RNP granules. Elife 4:
e06807
Kumar S, Tepper K, Kaniyappan S, Biernat J, Wegmann S, Mandelkow EM,
Müller DJ, Mandelkow E (2014) Stages and conformations of the Tau
repeat domain during aggregation and its effect on neuronal toxicity. J
Biol Chem 289: 20318 – 20332
Lee G, Cowan N, Kirschner M (1988) The primary structure and heterogeneity
of tau protein from mouse brain. Science 239: 285 – 288
Lee K-H, Zhang P, Kim HJ, Mitrea DM, Sarkar M, Freibaum BD, Cika J,
Coughlin M, Messing J, Molliex A, Maxwell BA, Kim NC, Temirov J, Moore J,
Kolaitis R-M, Shaw TI, Bai B, Peng J, Kriwacki RW, Taylor JP (2016) C9orf72
dipeptide repeats impair the assembly, dynamics, and function of
membrane-less organelles. Cell 167: 774 – 788
Li X, Kumar Y, Zempel H, Mandelkow E-M, Biernat J, Mandelkow E (2011)
Novel diffusion barrier for axonal retention of Tau in neurons and its
failure in neurodegeneration. EMBO J 30: 4825 – 4837
Li P, Banjade S, Cheng H-C, Kim S, Chen B, Guo L, Llaguno M, Hollingsworth
JV, King DS, Banani SF, Russo PS, Jiang Q-X, Nixon BT, Rosen MK (2012)
ª 2018 The Authors The EMBO Journal 37: e98049 | 2018 19 of 21
Susanne Wegmann et al Tau droplets transition into aggregates The EMBO Journal
Phase transitions in the assembly of multivalent signalling proteins.
Nature 483: 336 – 340
Li C, Götz J (2017) Somatodendritic accumulation of Tau in Alzheimer’s
disease is promoted by Fyn-mediated local protein translation. EMBO J 36:
3120 – 3138
Lim S, Haque MM, Kim D, Kim DJ, Kim YK (2014) Cell-based models to
investigate Tau aggregation. Comput Struct Biotechnol J 12: 7 – 13
Lin Y, Protter DSW, Rosen MK, Parker R (2015) Formation and maturation of
phase-separated liquid droplets by RNA-binding proteins. Mol Cell 60:
208 – 219
Lodish H, Berk A, Zipursky S (2000) Intracellular ion environment and
membrane electric potential. In Molecular cell biology, Tenney S, Ahr K,
McCaffrey P, O’Neal B, Steyn R (eds), 4th edn, pp 1 – 5. New York: W.H.
Freeman
Mair W, Muntel J, Tepper K, Tang S, Biernat J, Seeley WW, Kosik KS,
Mandelkow E, Steen H, Steen JA (2016) FLEXITau: quantifying post-
translational modifications of tau protein in vitro and in human disease.
Anal Chem 88: 3704 – 3714
Mitrea DM, Kriwacki RW, Handwerger KE, Cordero JA, Gall JG, Fox AH,
Lamond AI, Lamond AI, Spector DL, Cioce M, Lamond AI, Brangwynne CP,
Mitchison TJ, Hyman AA, Brangwynne CP, Eckmann CR, Courson DS,
Rybarska A, Hoege C, Gharakhani J et al (2016) Phase separation in
biology; functional organization of a higher order. Cell Commun Signal 14:
1
Molliex A, Temirov J, Lee J, Coughlin M, Kanagaraj AP, Kim HJ, Mittag T,
Taylor JP (2015) Phase separation by low complexity domains promotes
stress granule assembly and drives pathological fibrillization. Cell 163:
123 – 133
Monahan Z, Ryan VH, Janke AM, Burke KA, Rhoads SN, Zerze GH, O'Meally R,
Dignon GL, Conicella AE, Zheng W, Best RB, Cole RN, Mittal J, Shewmaker
F, Fawzi NL (2017) Phosphorylation of the FUS low‐complexity domain
disrupts phase separation, aggregation, and toxicity. EMBO J 36:
2951 – 2967
Mondragón-Rodríguez S, Basurto-Islas G, Santa-Maria I, Mena R, Binder LI,
Avila J, Smith MA, Perry G, García-Sierra F (2008) Cleavage and
conformational changes of tau protein follow phosphorylation during
Alzheimer’s disease. Int J Exp Pathol 89: 81 – 90
Morris M, Knudsen GM, Maeda S, Trinidad JC, Ioanoviciu A, Burlingame AL,
Mucke L (2015) Tau post-translational modifications in wild-type and
human amyloid precursor protein transgenic mice. Nat Neurosci 18:
1183 – 1189
Mukrasch MD, Bibow S, Korukottu J, Jeganathan S, Biernat J, Griesinger C,
Mandelkow E, Zweckstetter M (2009) Structural polymorphism of 441-
residue Tau at single residue resolution. PLoS Biol 7: 0399 – 0414
Mukrasch MD, Von Bergen M, Biernat J, Fischer D, Griesinger C, Mandelkow E,
Zweckstetter M (2007) The “jaws” of the tau-microtubule interaction. J
Biol Chem 282: 12230 – 12239
Murakami T, Qamar S, Lin JQ, Schierle GSK, Rees E, Miyashita A, Costa AR,
Dodd RB, Chan FTS, Michel CH, Kronenberg-Versteeg D, Li Y, Yang SP,
Wakutani Y, Meadows W, Ferry RR, Dong L, Tartaglia GG, Favrin G, Lin WL
et al (2015) ALS/FTD mutation-induced phase transition of FUS liquid
droplets and reversible hydrogels into irreversible hydrogels impairs RNP
granule function. Neuron 88: 678 – 690
Nott TJ, Farber P, Petsalakis E, Jervis D, Baldwin AJ, Forman-kay JD (2014)
Phase separation of disordered protein in the formation of membrane-
less organelles. Biophys J 106: 35a
Nott TJ, Petsalaki E, Farber P, Jervis D, Fussner E, Plochowietz A, Craggs TD,
Bazett-Jones DP, Pawson T, Forman-Kay JD, Baldwin AJ (2015) Phase
transition of a disordered nuage protein generates environmentally
responsive membraneless organelles. Mol Cell 57: 936 – 947
Patel SS, Belmont BJ, Sante JM, Rexach MF (2007) Natively unfolded
nucleoporins gate protein diffusion across the nuclear pore complex. Cell
129: 83 – 96
Patel A, Lee HO, Jawerth L, Maharana S, Jahnel M, Hein MY, Stoynov S,
Mahamid J, Saha S, Franzmann TM, Pozniakovski A, Poser I, Maghelli N,
Royer LA, Weigert M, Myers EW, Grill S, Drechsel D, Hyman AA, Alberti S
(2015) A liquid-to-solid phase transition of the ALS protein FUS
accelerated by disease mutation. Cell 162: 1066 – 1077
Pir GJ, Choudhary B, Mandelkow E, Mandelkow E-M (2016) Tau mutant
A152T, a risk factor for FTD/PSP, induces neuronal dysfunction and
reduced lifespan independently of aggregation in a C. elegans Tauopathy
model. Mol Neurodegener 11: 33
Reynolds C, Garwood C, Wray S, Price C, Kellie S, Perera T, Zvelebil M, Yang A,
Sheppard P, Varndell I, Hanger D, Anderton B (2008) Phosphorylation
regulates tau interactions with Src homology 3 domains of
phosphatidylinositol 3-kinase, phospholipase Cgamma1, GrB2 and Src
family kinases. J Biol Chem 283: 18177 – 18186
Salminen A, Kauppinen A, Suuronen T, Kaarniranta K, Ojala J (2009) ER stress
in Alzheimer’s disease: a novel neuronal trigger for inflammation and
Alzheimer’s pathology. J Neuroinflammation 6: 41
Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes
A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C,
Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tau
suppression in a neurodegenerative mouse model improves memory
function. Science 309: 476 – 481
Santa-María I, Pérez M, Hernández F, Avila J, Moreno FJ (2006)
Characteristics of the binding of thioflavin S to tau paired helical
filaments. J Alzheimers Dis 9: 279 – 285
Sawyer WH, Puckridge J (1973) The dissociation of proteins by chaotropic
salts. J Biol Chem 248: 8429 – 8433
Schmidt HB, Görlich D (2016) Transport selectivity of nuclear pores,
phase separation, and membraneless organelles. Trends Biochem Sci 41:
46 – 61
Schmidt HB, Rohatgi R (2016) In vivo formation of vacuolated multi-phase
compartments lacking membranes cell reports report in vivo formation of
vacuolated multi-phase compartments lacking membranes. Cell Rep 16:
1 – 9
Schwalbe M, Biernat J, Bibow S, Ozenne V, Jensen MR, Kadavath H,
Blackledge M, Mandelkow E, Zweckstetter M (2013) Phosphorylation of
human tau protein by microtubule affinity-regulating kinase 2.
Biochemistry 52: 9068 – 9079
Shin Y, Berry J, Pannucci N, Haataja MP, Toettcher JE, Brangwynne CP (2017)
Spatiotemporal control of intracellular phase transitions using light-
activated optoDroplets. Cell 168: 159 – 171.e14
Sillen A, Leroy A, Wieruszeski JM, Loyens A, Beauvillain JC, Buée L, Landrieu I,
Lippens G (2005) Regions of tau implicated in the paired helical fragment
core as defined by NMR. ChemBioChem 6: 1849 – 1856
Simic G, Babic Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milosevic N,
Bazadona D, Buée L, de Silva R, Di Giovanni G, Wischik C, Hof PR (2016)
Tau protein hyperphosphorylation and aggregation in Alzheimer’s disease
and other tauopathies, and possible neuroprotective strategies.
Biomolecules 6: 6
Spillantini MG, Goedert M (2000) Tau mutations in familial frontotemporal
dementia. Brain 123(Pt 5): 857 – 859
Stoothoff WH, Johnson GVW (2005) Tau phosphorylation: physiological and
pathological consequences. Biochim Biophys Acta 1739: 280 – 297
20 of 21 The EMBO Journal 37: e98049 | 2018 ª 2018 The Authors
The EMBO Journal Tau droplets transition into aggregates Susanne Wegmann et al
Takeda S, Wegmann S, Cho H, DeVos SL, Commins C, Roe AD, Nicholls SB,
Carlson GA, Pitstick R, Nobuhara CK, Costantino I, Frosch MP, Müller DJ,
Irimia D, Hyman BT (2015) Neuronal uptake and propagation of a rare
phosphorylated high-molecular-weight tau derived from Alzheimer’s
disease brain. Nat Commun 6: 8490
Taylor JP, Brown RH Jr, Cleveland DW (2016) Decoding ALS: from genes to
mechanism. Nature 539: 197 – 206
Tepper K, Biernat J, Kumar S, Wegmann S, Timm T, Hübschmann S, Redecke
L, Mandelkow EM, Müller DJ, Mandelkow E (2014) Oligomer formation of
tau protein hyperphosphorylated in cells. J Biol Chem 289: 34389 – 34407
Timm T, Li XY, Biernat J, Jiao J, Mandelkow E, Vandekerckhove J, Mandelkow
EM (2003) MARKK, a Ste20-like kinase, activates the polarity-inducing
kinase MARK/PAR-1. EMBO J 22: 5090 – 5101
Toretsky JA, Wright PE (2014) Assemblages: functional units formed by
cellular phase separation. J Cell Biol 206: 579 – 588
Uversky VN, Oldfield CJ, Dunker AK (2008) Intrinsically disordered proteins in
human diseases: introducing the D2 concept. Annu Rev Biophys 37:
215 – 246
Vallee RB, Borisy GG (1977) Removal of the projections from cytoplasmic
microtubules in vitro by digestion with trypsin. J Biol Chem 252: 377 – 382
Vanderweyde T, Apicco DJ, Youmans-Kidder K, Ash PEA, Cook C, Lummertz da
Rocha E, Jansen-West K, Frame AA, Citro A, Leszyk JD, Ivanov P, Abisambra
JF, Steffen M, Li H, Petrucelli L, Wolozin B (2016) Interaction of tau with
the RNA-binding protein TIA1 regulates tau pathophysiology and toxicity.
Cell Rep 15: 1455 – 1466
Von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow EM,
Mandelkow E (2001) Mutations of tau protein in frontotemporal dementia
promote aggregation of paired helical filaments by enhancing local b-
structure. J Biol Chem 276: 48165 – 48174
Von Bergen M, Barghorn S, Biernat J, Mandelkow EM, Mandelkow E (2005)
Tau aggregation is driven by a transition from random coil to beta sheet
structure. Biochim Biophys Acta 1739: 158 – 166
Walker LC, Diamond MI, Duff KE, Hyman BT (2013) Mechanisms of protein
seeding in neurodegenerative diseases. JAMA Neurol 70: 304 – 310
Wang Y, Garg S, Mandelkow E-M, Mandelkow E (2010) Proteolytic processing
of tau. Biochem Soc Trans 38: 955 – 961
Wegmann S, Medalsy ID, Mandelkow E, Müller DJ (2013) The fuzzy coat of
pathological human Tau fibrils is a two-layered polyelectrolyte brush. Proc
Natl Acad Sci USA 110: E313 – E321
Wildling L, Rankl C, Haselgrübler T, Gruber HJ, Holy M, Newman AH, Zou M-
F, Zhu R, Freissmuth M, Sitte HH, Hinterdorfer P (2012) Probing binding
pocket of serotonin transporter by single molecular force spectroscopy on
living cells. J Biol Chem 287: 105 – 113
Wille H, Drewes G, Biernat J, Mandelkow EM, Mandelkow E (1992) Alzheimer-
like paired helical filaments and antiparallel dimers formed from
microtubule-associated protein tau in vitro. J Cell Biol 118: 573 – 584
Wolozin B, Davies P (1987) Alzheimer-related neuronal protein A68: specificity
and distribution. Ann Neurol 22: 521 – 526
Wright PE, Dyson HJ (2014) Intrinsically disordered proteins in cellular
signalling and regulation. Nat Rev Mol Cell Biol 16: 18 – 29
Zempel H, Mandelkow E-M (2015) Tau missorting and spastin-induced
microtubule disruption in neurodegeneration: Alzheimer disease and
hereditary spastic paraplegia. Mol Neurodegener 10: 68
Zhang F, Roosen-Runge F, Sauter A, Roth R, Skoda MWA, Jacobs RMJ, Sztucki
M, Schreiber F (2012) The role of cluster formation and metastable liquid
—liquid phase separation in protein crystallization. Faraday Discuss
159: 313
Zhang X, Lin Y, Eschmann NA, Zhou H, Rauch JN, Hernandez I, Guzman E,
Kosik KS, Han S (2017) RNA stores tau reversibly in complex coacervates.
PLoS Biol 15: e2002183
Zhu S, Shala A, Bezginov A, Sljoka A, Audette G, Wilson DJ (2015)
Hyperphosphorylation of intrinsically disordered tau protein induces an
amyloidogenic shift in its conformational ensemble. PLoS One 10:
e0120416
License: This is an open access article under the
terms of the Creative Commons Attribution-
NonCommercial-NoDerivs 4.0 License, which permits
use and distribution in any medium, provided the
original work is properly cited, the use is non-
commercial and no modifications or adaptations are
made.
ª 2018 The Authors The EMBO Journal 37: e98049 | 2018 21 of 21
Susanne Wegmann et al Tau droplets transition into aggregates The EMBO Journal
